****

**Dr. El Shahawy**

**CURRICULUM VITAE**

**MAHFOUZ EL SHAHAWY, MD MS,**

**FACP, FACCP, FESC, FSCCT, FASH, FASPC, FAHA, FACC, ,**

**PRESIDENT INTERNATIONAL SOCIETY FOR CARDIOVASCULAR DISEASE PREVENTION**

**Lifetime Achievement Award for Practice of Medicine and Cardiology Sarasota, Florida [47 Years]**

**MD Suma Cum Laude First in Class “Sub Auspiciis Presidentis” with Ring of Honor bestowed by the Austrian President, in person, in a special Graduation Ceremony at the University of Vienna, Austria**

**Master of Science, Medicine/Cardiovascular Diseases; Mayo Clinic University of Minnesota**

**CLINICAL PROFESSOR OF MEDICINE, UNIVERSITIES OF FLORIDA AND SOUTH FLORIDA**

**Diplomat of the American Board of Internal Medicine and Cardiovascular Diseases**

**Diplomat of the Certification Board Cardiovascular Computed Tomography [CBCCT]**

**Golden Doctor Diploma 2014 University of Vienna, Austria**

**Level 111 Certification by the Society of Cardiovascular Computed Tomography [SCCT]**

**MEDICAL DIRECTOR CARDIOVASCULAR HEALTH ASSESSMENT CENTER**

**and**

**PRESIDENT OF CARDIOVASCULAR CENTER OF SARASOTA, FLORIDA, USA**

**Past Member Board of Trustees American Society of Preventive Cardiology (ASPC)**

**Past Member Board of Trustees and Secretary Association of Black Cardiologist (ABC)**

1950 Arlington Street, Suite 300

Sarasota, FL 34239

Telephone: 941-366-9800 FAX 941-366-2781

**E-mail:** [**mshahawy@cardiologycenter.net**](mailto:mshahawy@cardiologycenter.net) **Web Site:**[**www.cardiologycenter.net**](http://www.cardiologycenter.net)

DATE AND PLACE OF BIRTH: August 1, 1936 Cairo, Egypt

CITIZENSHIP: United States of America

MARITAL STATUS: Married

CHILDREN: One son and one daughter and four grandchildren

**UNDER-GRADUATE AND GRADUATE MEDICAL EDUCATION**

1955-1962: M.D. with top honor Summa cum Laude, first in class

University of Vienna, Vienna, Austria

M.D. Graduation Under the Auspiciis and in the presence of the Austrian

President, who personally bestowed the Golden Ring of Honor upon

Dr. Shahawy, The first and only non-Austrian in the history of Vienna

Medical School to achieve this honor still to this day.

“Summa cum Laude” With highest honor June 28, 1962

**POST-GRADUATE MEDICAL EDUCATION**

May 1962 – 1967 Elective Residency Training in Medicine and Cardiology

(Algemeines Krankenhaus)

General Hospital at University of Vienna; Vienna, Austria

July 1967 – 1968 Rotating Medical Internship

Flushing Hospital and Medical Center; New York, NY

July 1968 – 1970 Fellow in Medicine

Mayo Clinic; Rochester, MN

July 1970 – 1971 Research Fellow Medicine/Cardiovascular Diseases

Mayo Clinic; Rochester, MN

July 1971 – June 1973 Fellow/Teaching Fellow and Instructor in Cardiology

Medical College of Georgia; Augusta, Ga

**SPECIALTY CERTIFICATIONS AND POST GRADUATE DEGREES**

Master of Science, Medicine/Cardiovascular Diseases; Mayo Clinic University of Minnesota 1971

Certified by the Canadian Board of Internal Medicine (written) 1975

Certified by the American Board of Internal Medicine #034604 1977

Certified by the American Board of Cardiovascular Diseases #034604 1981

Diplomat of the Certification Board Cardiovascular Computed Tomography (CBCCT) 2010

Level III Re-certification by the Society of Cardiovascular Computed Tomography (SCCT) 2011

Level III Certification by the Society of Cardiovascular Computed Tomography (SCCT 2008

Diploma of Medicine/Cardiovascular Diseases; University of Vienna, Austria 1966

Diploma of Medicine; University of Vienna, Austria 1962

**STATE BOARD CERTIFICATIONS AND LICENSES**

E.C.F.M.G. (#63359) 1966

Florida State Board of Medical Examiners (#20619) 1973

Georgia State Board of Medical Examiners (#15621) 1973

“FLEX” (with reciprocity in 49 states) 1973

**OTHER CERTIFICATION(S)**

* Certification by the Florida Medical Association for “Instructional Program on

Accreditation for Continuing Medical Education” 1999/2000

* Basic and Advanced Cardiac Life Support by the American Heart Association May 2007
* Instructor for AHA BLS and ACLS courses 2007, 2014, 2020, 2021
* Certified by SCCT [Society for Cardiovascular Computed Tomography] Level 2 March 2008
* Certified by SCCT [Society for Cardiovascular Computed Tomography] Level 3 July 2008
* Certified by The Society for Academic Continuing Medical Education Dec 2016
* Good Clinical Practice for Clinical Research (GCP) May 2018

**CURRENT AND PAST MEMBERSHIP ON THE BOARD OF TRUSTEES/ BOARD OF GOVENORS OF NATIONAL AND INTERNATIONAL CARDIOVASCULAR ORGINZATIONS**

* International Society for Cardiovascular Disease Prevention (ISCVDP) 1987-Present
* American Society of Preventive Cardiology (ASPC) 2015-2018
* Association of Black Cardiologists (ABC) 2015-2017

**ACADEMIC APPOINTMENTS**

Aug 1997-Present Clinical Professor of Medicine; University of Florida

Feb 2007-Present Clinical Professor of Medicine; University of South Florida

1995-1997 Associate Clinical Professor of Medicine; University of Florida

1976-1995 Assistant Clinical Professor of Medicine; University of Florida

1976-1978 Assistant Clinical Professor of Medicine end Cardiology; University of South Florida

1973-1975 Assistant Professor of Medicine end Cardiology; University of Florida

1973-1973 Teaching Fellow and Instructor in Cardiology; Medical College of Georgia

**PROFESSIONAL SOCIETIES MEMBERSHIP**

**(Past and Present)**

* President International Society for Cardiovascular Disease Prevention **(ISCVDP)**
* Fellow American College of Cardiology (**FACC**)
* Fellow American Heart Association **(FAHA)**
* Fellow American Society of Prevention Cardiology **(FASPC)**
* Fellow European Society of Cardiology **(FESC)**
* Fellow American College of Physicians **(FACP)**
* Fellow American Society of Hypertension **(FASH)**
* Fellow Society Cardiovascular Computed Tomography **(FSCCT)**
* Fellow American College of Chest Physicians **(FACCP)**
* Platinum Member European Association of Preventive Cardiology **(EAPC)**
* Member World Heart Federation **(WHF)**
* Fellow American Heart Association “Council on Clinical Cardiology”
* Fellow American Society of Echocardiography
* Life Member of “The Doctors Mayo Society”
* Life Member of ABC [Association of Black Cardiologist]
* Life Member of the American Medical Society of Vienna Austria
* Life Member Florida Medical Association
* Life Member Sarasota County Medical Society
* Charter Member of the Plummer Society, Mayo Clinic Rochester, MN
* Honorary Member, Egyptian Society of Hypertension
* Member American Medical Association
* Member Mayo Alumni Association
* Member The New York Academy of Sciences
* Member Council on Critical Care, American College of Chest Physicians
* Member International Society for Holter & Non-invasive Electrocardiography (ISHNE)
* Member of the American Society of Hypertension in Black (ISHIB) [Life Member]
* Member Council for High Blood Pressure Research American Heart Association
* Member of National Lipid Association (NLA)
* Faculty Member for National CME Program: Expert Exchange Cardiovascular Disease/Member ”The Alliance for Continuing Education in the Health Professions”

**MEMBERSHIP OF PEER REVIEW JOURNALS**

* Member of the International Advisory Board of the Egyptian Heart Journal
* Member of the Clinical Geriatrics Advisory Board
* American Journal of Cardiology
* International Journal of Cardiovascular Imaging

**POSITIONS HELD (Past and Present)**

2016-Present **President International Society for Cardiovascular Disease Prevention** (**ISCVDP)**

5/2018- Present Co-chairman of Cardiovascular Disease Prevention Committee Association of Black

Cardiologists (ABC)

2015- 2018 Member, Board of Trustees American Society of Preventive Cardiology (ASPC)

2015-2018 Member and Secretary of Board of Governors for Association of Black Cardiologists (ABC)

2015-2018 Co-chairman Medical Education Committee of Association of Black Cardiologist (ABC)

2011- Present Medical Director Cardiovascular Health Assessment Center at Cardiovascular Center of Sarasota

2007-2011 Medical Director and Founder Cardiovascular Health Assessment Center Sarasota Memorial

2007- Present Medical Director for American Heart Association BLS/ACLS Course at SMH, Sarasota, FL

2007-2016 Member Institutional Review Board [IRB] Sarasota Memorial Hospital, Sarasota, FL

1995- Present President, Cardiovascular Center of Sarasota; Foundation for Medical Education and Research

1995- 2000 Medical Director, Cardiac Catheterization Lab; Doctors Hospital, Sarasota, FL

1991- 1992 Chairman, Long Term Investment Committee Sarasota County Public Hospital Board

1990- 1992 Elected Member, Board of Trustee; Sarasota County Public Hospital Board, Sarasota, FL

1989- 1995 President, Cardiovascular Institute of Sarasota, Sarasota, FL

1988- 1989 Chairman, Board of Trustees; Doctors Hospital, Sarasota, FL

1987- 1988 Vice-Chairman, Board of Trustees; Doctors Hospital, Sarasota, FL

1986- 1990 Member, Board of Trustees; Doctors Hospital, Sarasota, FL

1981- 1986 Member, Executive Committee of the Medical Staff; Doctors Hospital, Sarasota, FL

1980- 2004 Chairman, Medical Education Committee; Doctors Hospital, Sarasota, FL

1980- 1983 Chairman, Cardiac Committee; Doctors Hospital, Sarasota, FL

1987- 1988 Chairman, Cardiac Committee; Doctors Hospital, Sarasota, FL

1980- 1981 Chief of Medicine; Doctors Hospital, Sarasota, FL

1974- 1975 Director, Coronary Care Unit; Shands Teaching Hospital; University of Florida

1973- 1974 Director, Adult Cardiac Cath Lab; Shands Teaching Hospital; University of Florida

1973- 1974 Director, Heart Station; Shands Teaching Hospital; University of Florida

**HOSPTIAL AFFILATIONS (Past and Present)**

1975- Present Doctors Hospital- Sarasota, FL

2004- Present Sarasota Memorial Hospital- Sarasota, FL

2004- -2018 Lakewood Ranch Medical Center- Bradenton, FL

1986- Present Rehab Institute of Sarasota, Health South- Sarasota, FL

1975- 1983 Sarasota Memorial Hospital-Sarasota, FL

1973- 1975 Shands Teaching Hospital- Gainesville, FL

1971- 1973 Talmadge Teaching Hospital- Medical College of Georgia

1968- 1971 Methodist Hospital (Mayo Clinic) - Rochester, MN

1968- 1971 St. Mary’s Hospital (Mayo Clinic) – Rochester, MN

1967- 1968 Flushing Teaching Hospital (Algemeines Krankenhaus) – University of Vienna-Austria

1962-1967 General Hospital University of Vienna-Austria

**COMMITTEE MEMBERSHIPS (Past and Present)**

2016- Present Chairman Continuing Education Committee, International Society for Cardiovascular Disease

Prevention (ISCVDP)

1990- 2016 Chairman Continuing Education Committee, Cardiovascular Institute of Sarasota (CVIS)

2015- 2017 Member of Education Committee, American Society of Preventive Cardiology (ASPC)

2015- 2017 Member of Communication Committee, American Society of Preventative Cardiology (ASPC)

2014- Present Member, Cardiology Council, Doctors Hospital, Sarasota, FL

2007- 2016 Member Sarasota Memorial Hospital Institutional Review Board (IRB)

2005- Present Member Continuing Education Committee, Sarasota Memorial Hospital

2005- Present Member of the Pharmacy and Therapeutic Committee Sarasota Memorial Hospital

2003- Present Heart Failure Council – ISHIB

1999- Present Member Continuing Medical Education of ABC (American Black Cardiologists)

**PAST COMMITTEE MEMBERSHIPS**

2005- 2012 Member of the Pharmacy and Therapeutic Committee Doctors Hospital of Sarasota

1997- 2012 Member of the Continuing Education Committee of the American College of Cardiology

1990- 2010 Member of CME Committee Sarasota County Medical Society; Sarasota, FL

1998- 2007 Appointed Member by the President of the Florida Medical Association to “Committee

On Accreditation for Continuing Medical Education” for the State of Florida

1992- 2007 Member, Radiation Safety Committee; Doctors Hospital; Sarasota, FL

1995- 1998 Member, Medical Staff Credentials Committee; Doctors Hospital; Sarasota, FL

1994- 2000 Member, Institutional Review Board (I.R.B.); Doctors Hospital; Sarasota, FL

1994- 1998 Member, Pharmaceutical and Therapeutics Committee; Doctors Hospital; Sarasota, FL

1994- 2000 Chairman, Cardiology Advisory Council; Doctors Hospital; Sarasota, FL

1990- 1992 Member, Institutional Review Board; Sarasota Memorial Hospital; Sarasota, FL

1988- 1989 Member, Executive Committee; Rehab. Institute; Sarasota, FL

1980- 2000 Chairman, Electrocardiography Reading Panel; Doctors Hospital; Sarasota, FL

1984- 1987 Member, Credentials Committee; Doctors Hospital; Sarasota, FL

1984- 1985 Member, Bylaws Committee; Doctors Hospital; Sarasota, FL

1980- 1983 Member, Medical Privileges Committee; Doctors Hospital; Sarasota, FL

1988- 1990 Member, Medical Privileges Committee; Doctors Hospital; Sarasota, FL

1980- 1982 Member, Utilization Committee; Doctors Hospital; Sarasota, FL

1978- 1981 Member, Code C Committee; Sarasota Memorial Hospital; Sarasota, FL

1978- 1984 Member, Advisory Committee on Cardiac Reconditioning Program; YMCA.

1977- 1983 Member, Medical Advisory Committee; Sarasota Memorial Hospital Foundation.

1976- 1984 Member, Cardiac Intensive Care; Doctors Hospital; Sarasota, FL

1975- 1983 Member, Cardiac Committee; Sarasota Memorial Hospital; Sarasota, FL

**RESEARCH POSTITIONS**

1973- Present Principal Investigator for Several Clinical Research Protocols Phase II, III, IV, (As Listed Below)

1972- 1973 Instructor, Division of Cardiology and Hypertension; Medical College of Georgia

1970- 1971 Research Fellow, Department of Medicine and Physiology; Mayo Clinic; Rochester, MN

**AREAS OF RESEARCH INTERESTS**

**(See Publication Pages)**

Research Interests Include: **Cardiovascular Disease Prevention**, **Diabetes, Hypertension, Dyslipidemia, Obesity**, Clinical Trials, Cardiovascular Pharmacology, Disease Management and Clinical Outcomes. Served as Principal Investigator In Many National and International Trials Including Odyssey, Fourier, Ischemia, Merritt, Convinse, Bravo, Valiant, Affirm, Invest, Enable, Sportif V, RELY, Averroes, RedHF, Vertis, Exscel, Spire, Bayer, Orion, Flow, Warrior, Fidelio, Figaro, Vesalius and others as listed below

**Topics of Past and Current Research Interest Include:**

* Cardio Obesity/Excess Epicardial Fat
* Cardio-Renal Syndrome
* Novel Approach for Early Cardiovascular Health Assessment (CVHA)
* Obesity with emphasis on Cardio Obesity- Epicardial Fat as a novel risk marker
* Novel Management of Dyslipidemia Beyond Statin: PCSK9 Inhibitor
* Early Cardiovascular Health Assessment and Cardiovascular Disease Prevention
* Cardiovascular Computed Tomography
* Diabetic Heart and Kidney Disease
* Metabolic Syndrome
* Acute and Chronic Coronary Syndrome
* Heart Failure
* Hypertension
* Atrial Fibrillation and Stroke Prevention
* Deep Vein Thrombosis Prevention and Treatment
* Coronary Calcium and Cardiovascular Risk
* Echocardiography/Doppler
* Cardiac Hemodynamic-Catheterization
* Thyrocardiac Disorders
* HIS Bundle Electrophysiology
* Cardiomyopathies with Particular Reference to the Role of Electrolytes and Trace Metals, such as Magnesium and Potassium
* Renin-Angiotensin-Aldosterone System
* Peripheral Arterial Disease

**Current Clinical Cardiovascular Research Includes Use of Newer Drugs in the Treatment of:**

* Diabetic Heart and Kidney Disease: Finerenone (Kerendia)
* Hyperlipidemia with focus on PCSK9 Inhibitors: Alirocumab (Praluent) and Evolucomab (Repatha)

And siRNA’s: Inclisiran (Leqvio) and CETP inhibitor (Obicetrapib)

* Obesity and perivascular adiposity
* Excess Epicardial Fat Volume
* Metabolic Syndrome
* Hypertension (Firibastat)
* Diabetic Heart Disease
* Coronary Artery Disease
* CHF
* Peripheral Arterial Disease
* Atrial Fibrillation (Asundexian)
* Deep Vein Thrombosis treatment with Novel Oral Anticoagulants
* Cardio Renal Syndrome in Diabetics
* Non-Obstructive Coronary Artery Disease in Women

**Participation as Principal Investigator in Over 100 Clinical Cardiovascular Research Trials Involving Multi-National Centers (as listed below)**

1. **Amgen** Protocol No. “A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing The Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) (OCEAN(a)”

August 2023-Present

1. **Novartis** Protocol No*.* CKJX839D12302 “A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)”

August 2023-Present

1. **Janssen** Protocol No. 70033093ACS3003: “A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome”

February 2023- Present

1. **Janssen** Protocol No. 70033093AFL3002: “A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Subjects with Atrial Fibrillation”

February 2023- Present

1. **Amgen** Protocol Number 20200117: The African American Heart Study: A Real-World Data Study of Atherosclerotic Cardiovascular Risk in African American and Black Participants in the US

September 2022- Present

1. **BROOKLYN** Protocol TA-8995-301: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies: A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH and LDL-C 70 mg/dL Who are Not Adequately Controlled by Their Lipid-Modifying Therapies

July 2022- Present

1. **OCEANIC-AF** (Atrial fibrillation) Protocol 19767: A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, 2-arm Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke July 2022- Present
2. **Amgen** Protocol 20180244: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) July 2022- 2023
3. **Amgen** Protocol 20210057: A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

Mar 2022- Present

1. **Victor MK1242-**PN035: A Phase III Double Blind, Placebo controlled Efficacy and Safety to Evaluate Heart Failure with Reduced Ejection Fraction with Verciguat

October 2021-Present

1. **REFRESH-**QGC001-3QG2: A Phase III Double Blind, Placebo controlled Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension

April 2021-Present

1. **HPS-4/TIMI 65/ORION-4:** A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease.

2020-2021

1. **FRESH:** “A Phase 3, Double-blind, Placebo controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects”

2020-Present

1. **Orion-8 Protocol number MDCO-PCS-17-05:** A long term extension trial of the Phase III lipid-lowering trials to assess the effect of long-term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C

2019- Present

1. **Novo Nordisk FLOW Protocol U1111-1217-6259:** FLOW -Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease

2019- Present

1. **Warrior Trial:** Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) project

2019- Present

1. **Amgen Vesalius-CV Protocol number 20170625:** A Double Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke 2019-Present
2. Factors Influencing the Development and Progression of Cardiovascular Disease in Men and Women Throughout Their Life Span – investigator-initiated study

2008 - Present

1. Calcium score as a predictor of CVD risk as compared with early cardiovascular disease risk score also known as Rasmussen Risk Score (RRS); could it be additive? – investigator-initiated Study 2008- Present
2. **Orion- 10 Protocol number MDCO-PCS-17-04:** A placebo-controlled, double-blind, randomized trial to evaluate the effect of 300 mg of inclisiran sodium given as subcutaneous injections in subjects with atherosclerotic cardiovascular disease (ASCVD) and elevated low‑density lipoprotein cholesterol

2017-2019

1. **Odyssey Legacy Protocol Number OBS15072** Long-term legacy effects of LDL-C lowering with alirocumab: observational follow-up of the ODYSSEY OUTCOMES study 2018
2. **SOLOIST-WHF Trial STUDY NUMBER: EFC15156:** : A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of SOtagLiflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes POST Worsening Heart Failure 2018-2020
3. **Kowa 301Protocol Number 301:** A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12- week Study With a 40 – Week, Active-Controlled, Double-Blind Extensions to Evaluate the Efficacy and Safety of K-877 in Adult patients With Fasting triglyceride Levels >500 mg/dL and < 2000 g/dL and Normal Renal Function 2017-2018
4. **Kowa 303 Protocol Number 303:** A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12- week Study With a 40 – Week, Active-Controlled, Double-Blind Extensions to Evaluate the Efficacy and Safety of K-877 in Adult patients With Fasting triglyceride Levels >500 mg/dL and < 2000 g/dL and Moderate Renal Function. 2017- 2018
5. **ISCHEMIA:** International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (May 2012-Present) Sponsored by the National Institute of Health (N.I.H}

2012 -2020

1. **Amgen OLE Protocol Number:** 20130295 A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease

Sept. 2016- Present

1. **Bayer Finerenone / 17530:** A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the safety and efficacy of finerenone, in addition to standard of care, on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease 2015-Present
2. **Bayer Finerenone / 16244:** A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the safety and efficacy of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease 2015-2020
3. **VERTIS: Ertugliflozin** (MK-8835/PF-04971729) in subjects with Type 2 Diabetes Mellitus and Established vascular disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to assess cardiovascular outcomes

June 2014-2020

1. **Choice II: EFC13786:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Primary Hypercholesterolemia not treated with a statin

2013- 2017

1. **ODYSSEY COMBO II: EFC11569:** A Randomized, Double Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 versus Ezetimibe in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy

April 2013 – 2016

1. **ODYSSEY OUTCOMES: EFC11570:** A Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Effect of SAR236553/REN727 on the Occurrence of Cardiovascular Experienced Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Mar 2013- 2018

1. **ODYSSEY/STATIN INTOLERANCE: R727-CL-1119:** Double-blind, Double Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins

Jan 2013 – 2017

1. **GLORIA-AF:** Global Registry on Long-Term Oral Anti-Thrombotic Treatment In Patients with Atrial

Fibrillation (phase II/III)

May 2012-2018

1. **SPIRE LL:** A 52 week, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of PF-04950615 in Subjects with Primary Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Feb. 2015-2016

1. **SPIRE I:** Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of PF 04950615, In Reducing The Occurrence Of Major Cardiovascular Events In High And Very High Risk Subjects Having a direct LDL-C measurement of >70 mg/dL and < 100 mg/dL 2015-2016
2. **SPIRE II:** Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of PF 04950615, In Reducing The Occurrence Of Major Cardiovascular Events In High And Very High Risk Subjects Having a direct LDL-C of >100 mg/dL

2015-2016

1. **MC-RMAH:** A Randomized, Placebo-Controlled, Double-Blinded, Parallel Phase 2a to Evaluate the Safety and Efficacy of LY262309 in Patients with Primary Hypertension

June 2014- 2015

1. **Exscel Study:** BCB109: A Randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus December 2013 – 2017
2. **ODYSSEY OPTION I:** R727-CL-1110: A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Atorvastatin versus Ezetimibe Added-on to Atorvastatin versus Atorvastatin Dose Increase versus Switch to Rosuvastatin in Patients Who are Not Controlled on Atorvastatin

May 2013 – 2015

1. **ODYSSEY OPTION II:** R727-CL-1118: A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin versus Ezetimibe Added-on to Rosuvastatin versus Rosuvastatin Dose Increase in Patients Who are Not Controlled on Rosuvastatin

May 2013 – 2015

1. **TASLY PHARMACEUTICALS: T89-07-CAESA:** A Phase III, Double Blind, Placebo-Controlled, Randomized, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of T89 in Patients with Chronic Stable Angina Pectoris

Jan 2013- 2015

1. **AMGEN/FOURIER:** 20110118: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease

Dec. 2012- Sept. 2016

1. **F. Hoffmann-La Roche Ltd:** **BC280287** A Phase 3B Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities

Nov 2012- July 2013

1. **ODYSSEY:** LTS11717: Long-term safety and tolerability of REGN727/SAR236553 in high cardiovascular risk Patients with hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, Double-blind, placebo-controlled study July 2012-2016

1. **LTOLE:** Averroes Long Term Open Label Extension Study
2. **AVERROES:** Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who have failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind trial; Protocol CV185048
3. **DUT-MD-304:** A phase III, randomized, Double-blind, placebo controlled, multicenter study to evaluate the Safety and efficacy of Dutogliptin in patients with type 2 Diabetes Mellitus on background treatment with Pioglitazone
4. **DUT-MD-303:** A phase III, randomized, Double-blind, placebo controlled, multicenter study to evaluate the safety and efficacy of Dutogliptin in patients with type 2 Diabetes Mellitus on background treatment with Glimepiride with or without Metformin
5. **CFD 109701:** The incidence of orthostatic hypotension with the co-administration of CR formulation of Carvedilol in a fixed dose combination product with Lisinopril
6. **CV185048:** Apixaban versus Acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment, a randomized, double blind trial
7. **DAIICHI-SANKYO:** A prospective, open label, single arm study to evaluate the safety and efficacy of an Olmesartan medoxomil based treatment regimen in elderly patients with hypertension
8. **FOREST:** A prospective, randomized, open label, parallel group study to compare the tolerability of Nabivolol to other beta blockers in patients with stage I or II hypertension
9. **TAKEDA:** A phase 3 randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of TAK- 491 in subjects with essential hypertension
10. **DAR 312:** A phase 3 randomized, double blind, placebo, and active controlled, multi-center study to evaluate the safety and efficacy of Darusentan in subjects with resistant hypertension receiving combination therapy with three or more antihypertensive drugs including a diuretic as compared to Guanfacine
11. **DAR 312-E:** A double blind, active controlled, long term safety extension study of optimized doses

Of Darusentan in subjects with resistant hypertension despite receiving combination therapy of three or more antihypertensive drugs including a diuretic as compared to Guanfacine

1. **ABBOT:** Protocol #MO5-748 A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Rosuvastatin Calcium Combination Therapy to Fenofibric Acid and Rosuvastatin Calcium Monotherapy in Subjects with Mixed Dyslipidemia

February 2006-2008

1. **AGLESS:** Novartis Pharmaceuticals trial entitled: “A 36 week randomized, double-blind, parallel-group, multicenter, active-controlled, optional titration study comparing an aliskiren-based regimen to a Lisinopril- based regimen in patients > 65 years old with systolic essential hypertension” Protocol Number: CSPP100A23449 Jan.2006-2008
2. **ATHENA:** Protocol #EFC 5555 - A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atrial Fibrillation/Atrial Flutter (AF/AFL)IND # 49,484

July 2005-2009

1. **COREG (CFD105453):** A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment with 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40mg QD Doses of Lisinopril (Zestril) or a Combination of One of the Doses of Each Medication Aug.2006- 2008
2. **DAR 311-DORADO:** Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Four or More Antihypertensive Drugs, Including a Diuretic May 2006- 2009
3. **DAR-311-E - DORADO-EX:** A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension: A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Four or More Antihypertensive Drugs, Including a Diuretic

Sept. 2006- 2009

1. **FOCUS**: Protocol AGI-1067-051: Follow up of Clinical Outcomes: The Long-term AGI-1067 plus Usual Care Study

Aug. 2006-2008

1. **PROTECT:** A multicenter, randomized, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy. Protocol Number: CKI-301 July 2006-June 2009
2. **PROVIDENCE-1:** Prospective, Randomized, Double-Blind (Phase 3) Study of Rifalazil Treatment On the Number of Vascular Interventions and Peripheral Vascular Disease Endpoints in Chlamydia Pneumoniae Seropositive Patients Protocol #ABI-1648-022
3. **RedHF:** A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia Protocol Number: 20050222 March 2006-2014

1. **RELY:** Randomized Evaluation of Long-term anticoagulant therapy comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients With non-valvular atrial fibrillation: prospective, multi-center, parallel-group, non-inferiority trial (RE-LY STUDY)

November 2005-2007

1. **TREAT:** Protocol # 20010184,IND Number: BB IND-11621, Trial to Reduce Cardiovascular Events with Aranesp® Therapy Sept.2004- 2009
2. **APEX:** Protocol # 2003056 A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

June 2004-May 2006

1. **ARISE:** Protocol #AGI-1067-042 Aggressive Reduction of Inflammation Stops Events

June 2003- August 2006

1. **AMADEUS:** Protocol A multicenter, randomized, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous idraparinux (SanOrg 34006) with adjusted-dose oral vitamin-K antagonists in the prevention of thromboembolic events in patients with atrial fibrillation.

Sept.2003-March 2006

1. **BMC Hypertension study:** The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension (CV131176)

November 2005- March 2006

1. **COREG( 105517)/ 103560:** A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG™ MR) and Metoprolol Succinate Extended Release (Toprol-XL®) on the Reduction of Microalbuminuria in Patients with Hypertension and Microalbuminuria.

May 2005- 2007

1. **EVEREST:** Protocol # 156-03-236 Multicenter, Randomized, Double-blind, Placebo-controlled study to evaluate the long term efficacy and safety of oral Tolvaptan tablets in subjects hospitalized with worsening congestive heart failure.

Aug.2003 - 2005

1. **NOVACARDIA STUDY:** A randomized, double-blind, placebo controlled, dose escalation study of the effects of KW-3902 on diuresis in patients with congestive heart failure (CHF) refractory to high dose diuretic therapy

July 2005-Jan. 2006

1. **Novartis Pharmaceuticals Trial:** A 6-week, multicenter, randomized, double-blind, parallel-group study to evaluate the combination of valsartan/HCTZ (160/12.5mg with forced titration to a maximum dose of

320/25mg) compared to valsartan monotherapy (160mg with forced titration to 320mg) as initial therapy in patients with severe hypertension. Protocol Number: CVAH631D2301

Nov.2005-2006

1. **ONO-5129POU006:** Randomized double-blind, placebo-controlled pharmacodynamics evaluation of Ono-5129 in patients with treatment naïve type II Diabetes mellitus

May 2005-December 2006

1. **TRIUMPH- Protocol:** A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate Injection in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction, or "The TRIUMPH Study: Tilarginine Acetate Injection in a Randomized International Study in Unstable AMI Patients/Cardiogenic Shock" June 2005- 2006
2. **TROPIC-** Protocol MA-03010401The dose response of Niacin ER/Lovastatin on peak walking time in patients with intermittent Claudication – a Matrix design

July 2003 –2005

1. **A-Heft (African American Heart Failure Trial):** Protocol A placebo-controlled trial of BiDil Added to standard therapy in African American patients with heart failure.

2003-July 2004

1. **AVALIDE:** Protocol #L8829 (CV131-170) The efficacy and safety of Avalide 150/12.5 mg, and Avalide

300/25 mg in patients with hypertension uncontrolled on monotherapy.

June 2003- July 2004

1. **AVANDIA 347:** Protocol BRL 49653C/347 A Multicenter, Randomized, Double-Blind, Parallel- Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 weeks in Subjects with Type 2 Diabetes Mellitus Who are Inadequately Controlled on Insulin

March 2003-March 2004

1. **DAR 201:** Protocol# A Phase II Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic

July 2004- 2006

1. **ICPOP:** The Effect of Niacin ER/Lovastatin on Peak Walking Time in Patients with Intermittent Claudication

May 2004 – 2006

1. **NAVIGATOR:** Protocol # CDJN608B2302 Novartis Pharmaceuticals trial entitled: A multinational, randomized, double-blind, placebo-controlled, forced-titration, 2 x 2 factorial design study of the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance (IGT) July 2003- 2008
2. **TAK 536:** A Phase II, Double-Blind, Randomized, Placebo-Controlled, Dose-ranging Study of the Efficacy, Safety, and Tolerability of TAK-536 in Patients with Mild to Moderate Uncomplicated Essential Hypertension -01-03-TL-536-002

Aug. 2004-2006

1. **TAK 525:** A Phase II Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety and Tolerability of Pioglitazone HCl (ACTOS®) in combination with TAK-536 in Subjects with Type 2 Diabetes Protocol #: 01-04-TL-OPI-525

Aug 2004-June 2005

1. **TAKEDA MCC-135-** Protocol No.: 01-02-TL-MCC135-001A Phase II, Double- Blind, Randomized Exploratory, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of MCC-135 Comparing QD Vs BID Doses in Subjects with Congestive Heart Failure, NYHA Class II/III

Sep 2002-2004

1. **SOLAR-** Protocol-4522US/0003:A Randomized,Open-Label,3-ArmParallel-group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin with Atorvastatin and Simvastatin Achieving NCEP ATP III LDL-C Goals in High-.risk Subjects with Hypercholesterolemia in the Managed Care Setting

July 2002-2004

1. **EXCLAIM-** Protocol XRPA4563C/3501: A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely III Medical Patients with Prolonged Immobilization 2002- 2004
2. **NEB - 203** A Double-Blind, Randomized, Multi-Center , Five Treatment Study Of The Effects Of Nebivolol Compared To Atenolol On Cardiovascular Hemodynamics And Exercise Capacity In Patients With Mild To Moderate Hypertension- Protocol #NEB-203 March 2002- 2004
3. **COREG 105517/ 347:** A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on Glycemic Control in Hypertensive Patients with Type II Diabetes Mellitus-SB 105517/347

March 2002- 2004

1. **ADVANCE-CVAH631AUS01:** “A Double Blind, Randomized, Parallel Group Study Comparing the Effects of Diovan HCT® 160/12.5mg to Amlodipine 10mg in African American Patients with Mild to Moderate Hypertension.

Dec 2001-2003

1. **Mitsubishi Protocol:** A Phase II, Double-Blind, Randomized, Placebo Controlled, Dose Comparative Study of the Efficacy, Tolerability and Safety of MCC-135 in Subjects with Chronic Heart Failure, NYHA Class II/III

March 2001-2003

1. **CRISP:** “A Single- Arm, Open Label Study of Cerivastatin (Baycol) In Community- Based Patients With Hypercholesterolemia At Risk For Cardiovascular Disease And Patients With Cardiovascular Disease”

Dec. 2000-August 2000

1. **Protocol DTI-0009/003:** Phase II, Multi-Center, Double-Blinded, Placebo-Controlled, Dose- Finding Efficacy and Safety Study of the A1-Adenosine Receptor Agonist DTI-0009 Administered Intravenously to Patients with Atrial Fibrillation Dec.2000-2001
2. **EPERELONE:** A Double Blind, Randomized, Placebo-Controlled Trial Evaluating The Safety and Efficacy of Eplerenone in Patients with Heart Failure Following Acute Myocardial Infarction, IND #51,780

Dec. 2000-May 2001

1. **OCTAVE:** Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril – Protocol #: CV 137120 Nov. 2000-June 2001
2. **SPORTIF V:** Efficacy & Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke & Systemic Embolic Events in Patients with Atrial Fibrillation Protocol #: 233 (SH-TPA-0005) July 2000-2004
3. **TAKEDA 504:** A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCI vs. Glyburide in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild to Moderate CHF - Protocol #: 01-00-TL-OPI-504

May 2000-2002

1. **TAKEDA 520:** A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCL vs Glyburide in the Treatment of Subjects with Type 2(Noninsulin Dependent) Diabetes Mellitus and Mild Cardiac Disease(NYHA I)
2. **BRAVO:** “Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion” Protocol Number: SB 214857/030

1999-2000

1. **ENABLE-2:** "Endothelins Antagonist Bosentan for Lowering Cardiac Events in Heart Failure”: Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effects of Ro 47-0203 (Bosentan) on the Morbidity and Mortality of Patients with Chronic Heart Failure (Bosentan), March 1999-2002
2. **VALIANT:** “Valsartan In Acute myocardial infarctions”: Multinational, Multicenter, Double-Blind, Randomized, Active Controlled, Parallel Group Study Comparing The Efficacy And Safety Of Long-Term Treatment With Valsartan, Captopril And Their Combination In High-Risk Patients After Myocardial Infarction,

February 1999-2001

1. **OPUS ORBOFIBAN STUDY** 159-97-02-026: OPUS-T1MI 16: A Phase III, International Randomized, Double Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Orbofiban in Patients with Unstable Coronary Syndromes. IND No. 49, 380.

May 1998-1999

1. **AFFIRM TRIAL:** “Atrial Fibrillation Follow-up Investigation of Rhythm Management”: Sponsored by National Heart, Lung, and Blood Institute, National Institutes of Health.

May 1998-2001

1. Randomized, Open-Label, Active Controlled, Multicenter Phase III Safety study of Two Doses of **NATRECOR (BNP)** Administered as a Continuous Infusion in Treatment of Decompensated CHF.

1997-Completed

1. **INVEST** (International Verapamil-Trandolopril Study) is a Randomized, Controlled, Clinical Trial Comparing a Calcium Antagonist Treatment Strategy (Isoptin SR) with a Non-Calcium Antagonist Treatment Strategy for the Control of Hypertension in Primary Care Coronary Artery Disease Patient Population
2. A Randomized, Placebo-Controlled, Parallel-Group Study of **C-866** with Long-Term Safety Evaluation In Patients with Essential Hypertension.

1997-Completed

1. **REACH I TRIAL:** A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effects of Ro 470203 (Bosentan) on the Morbidity and Mortality of Patients with Chronic Heart Failure.

1997-1998 Completed

1. **REACH II TRIAL OPEN-LABEL:** Long-Term study in Patients with Chronic Heart Failure who participated in Controlled Clinical Studies with Bosentan.

1997-Completed

1. **MERIT:** A Double-Blind, Placebo Controlled Survival Study with Toprol XL in Patients with Decreased Ejection Fraction and Symptoms of Heart Failure. MERIT, SH-MET 0024, #830-30.

1997-Completed

1. **CONVINCE:** “Controlled Onset Verapamil Investigation of Cardiovascular Endpoints”: IND #39.459, 26-96-02-011. 1996-2001
2. **RENAAL:** “A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients with NIDDM and Nephropathy” (MERCK PROTOCOL 147). 1996-2001
3. **AZIMILIDE:** “An Open-Label Clinical Trial to Assess the Long-Term Safety of Azimilide in Patients with Atrial Fib/Flutter and/or Paroxysmal Supraventricular Tachycardia” # 1995011.

1995-Completed

1. **TRANDOLAPRIL in HYPERTENSION:** Effectiveness When Added to Verapamil SR TARKA TV-48-

HTN

1995-1997

1. A Double-Blind, Placebo-Controlled, Parallel, Design Clinical Trial to Assess the Safety and Efficacy of 100 Mg of **Azimilide** for the Prophylactic Treatment of Symptomatic Atrial Fibrillation/Flutter and/or symptomatic Paroxysmal Supraventricular Tachycardia No. 1995010 1995-1997

1. A Double-Blind, Randomized, Placebo-Controlled, Parallel Design Trial of Twelve to Fourteen weeks Duration to Determine the Effect of Food on Anti-hypertensive Response of **CGP 48933** 80-Mg in Patients with Mild to Moderate Essential Hypertension.

1993-1995

1. **Dose Ranging Study of Oral Bidsomide vs. Placebo** in Reducing the Recurrence of Symptomatic Atrial Fibrillation/Flutter and Paroxysmal Supraventricular Tachycardia NP8-92-02-046. 1993-1995
2. **CARDIZEM CD ANGINA STUDY:** Protocol #DZPROI64.

1993

1. **MINITRAN MULTICENTER EXERCISE TOLERANCE EFFICIENCY TRIAL:** Protocol R-834-T- 018,

1992-1993

1. **ANTI-COAGULATION:** Initiation and Maintenance Study Protocol # CDE-COU-8901. 1991
2. **KERLONE:** Hypertension Clinical Evaluation. 1990
3. **NICARDIPINE STUDY:** Protocol #LAB/NICC019/USA.

1988-1989

1. The Effect of **AMIODARONE** on Malignant Cardiac Arrhythmias. Protocol #IND 21-612. 1981-1982
2. **INOCOR in REFRACTORY CONGESTIVE HEART FAILURE STUDY:** Protocol #P-272

1981-1982

**SIGNIFICANT ACHIEVEMENTS:**

* Dr. El Shahawy Day February 4, 2022 by City of Sarasota Mayor February 4, 2022
* Lifetime Achievement Award City of Sarasota for Medical Service over 47 years February 4, 2022
* Doctor of Distinction 2022 Sarasota Scene Magazine January 2022
* Co-Chairman X International Conference on Arterial Hypertension and Cardiovascular Disease Prevention

Vitebsk, Belarus, May 30-31, 2019

* Invitation to judge the Abstracts submitted for the Annual Congress of European Society of Cardiology for August 2019 2019
* Certificate of Appreciation from CardioPrevent 2018 Preventive Cardiology & Rehabilitation Working Group in recognition of scientific activity and enriching the program with new data as an international speaker November 2018
* Invitation to judge the Abstracts submitted for the Annual Congress of European Society of Cardiology for August 2018 2018
* Established and directed International Cardiovascular Education congress with emphasis on early

Cardio Vascular Disease Prevention, This congress being held annually for the last 28 years in the Summer in different Countries on all five continents, this symposium is being hosted by nationally renowned professors from the U.S. but also included international faculty and members and leaders of the Society of Cardiology of the host country 1990-Present

* Established and directed International Cardiovascular Education congress with emphasis on early

Cardio Vascular Disease Prevention, this congress being held annually for the last 27 years in the Summer in different Countries on all five continents, this symposium is being hosted by nationally renowned professors from the U.S. but also included international faculty and members and leaders of the Society of Cardiology of the host country 1990-Present

* Started and directed The National Cardiovascular Symposium/ Congress being held in Sarasota in the month of February “Heart Month” every year for the past 18 years and it is being hosted by National renowned Professor of Cardiology from the most prestige institution in the country like mayo clinic, Cleveland Clinical, Harvard, UF, and many more 1986-Present
* **Europrevent Diploma 2017 Top Presentation Award for best scientific work in Diabetes, Dyslipidemia and Obesity 2017**
* **Received Golden Doctor Diploma from University of Vienna, Austria 2014**
* Established first adult Cardiac Computed Tomography Program at SMH 2009
* Established and directed first Cardiac Preventive Program at Sarasota Memorial Hospital 2008
* Established and directed the Cath Lab at Doctors Hospital Of Sarasota 1997
* Established first Echocardiography lab at Sarasota Memorial Hospital (SMH) 1976
* Instrumental as first Cardiologist in getting Cath lab established at Sarasota Memorial Hospital (SMH) 1975/76
* Established the first adult Echo Cardiograph Lab” Heart Station” Cardiac Non-Invasive Lab at University of Florida (U.F.) 1973
* Established and directed the first Cardiac Intensive Care Unit at University of Florida (U.F.) 1973
* Achievement Award from the Egyptian President for achievement in Vienna medical school 1962
* **Received the Austrian Republic Ring of Honor from the Austrian President (Dr. Shahawy** was the first and only Non-Austrian in the history of Vienna Medical School to achieve this honor still to this day.)   
   1962
* **MD, Summa Cum Laude, Under the Auspiciis of the Austrian President "Sub Auspiciis Presidentis" first in class 1962**

**OTHER SIGNIFICANT ACHIEVEMENTS:**

1. **Founder of:**
2. First coronary intensive care unit at the University of Florida 1973
3. Establishment first noninvasive cardiovascular laboratory at the University of Florida 1973
4. Co-founder of the Cardiac Cath Laboratory at Sarasota Memorial Hospital 1976
5. Establishment of the first Cardiac Computed Radiation Laboratory Doctors Hospital of

Sarasota 1990

1. Establishment of the Cardiovascular Disease Assessment Center at Sarasota Memorial Hospital

2008

1. Co-founder first Cardiovascular Computed Tomography Program at Sarasota Memorial Hospital

2008

1. Establishment of the Cardiovascular Disease Assessment Center at Cardiovascular Center of Sarasota 2012
2. **Life membership in the following National and International Organizations:**
3. Mayo Doctors Society, Mayo Clinic Rochester, Minnesota
4. Austrian American Medical Society of Vienna/Austria
5. International Society of Hypertension in Black (ISHIB)
6. Association of Black Cardiologists (ABC)

**TOP HONORS**

* **MD, Summa Cum Laude, Under the Auspiciis of the Austrian President "Sub Auspiciis Presidentis" first in class 1962**
* **Received the Austrian Republic Ring of Honor from the Austrian President (Dr. Shahawy** was the first and only Non-Austrian in the history of Vienna Medical School to achieve this honor still to this day.) 1962
* Achievement Award from the Egyptian President for achievement t in Vienna medical school 1962
* Nomination for the Distinguished Mayo Clinic Alumnus Award 1998
* Elected Life Member in “The Mayo Doctors Society” 1998
* Distinguished Physician of the Florida Medical Association “A Physician Who Cares” Aug 2000
* City of Sarasota Proclamation Aug 2000
* City of Sarasota Mayor Citation and Proclamation for Community Service for the last 30 years 2006
* City of Sarasota Mayor Citation and Proclamation for Community Medical Education Mar 2007
* Proclamation of Sarasota County Commissioner for Establishing the first Successful Cardiovascular Disease Assessment and Prevention Center at Sarasota Memorial Hospital presented by Commissioner Carolyn Mason to Dr. El Shahawy at the Fifth Annual Cardiovascular Symposium at SMH which was organized and chaired by Shahawy February 2009
* Doctors of Philanthropy conveyed by the Board of Directors of Sarasota Memorial Health Care

Foundation at the Annual Meeting Dec 2009

* Doctor of Philanthropy Sarasota Memorial Hospital 2012
* **Golden Doctor Diploma by University of Vienna** for scientific achievement in last four decades June 2014
* Nominated for the Board of Trustee for The American College of Cardiology (ACC) 2016
* **Winner of Diploma for best original scientific work in the category of Diabetes, Lipids and Obesity** presented at the Annual Congress of the European Society of Preventive Cardiology and Rehabilitation in Malaga, Spain April 2017
* Award for Gratitude and Appreciation for Participation for Cardiovascular Disease Prevention in Egypt from the Minister and Governor of Al-GHARBIA/Egypt Feb 2018
* ABC Chairman’s Award presented at the Annual Meeting of the ABC in conjunction with Annual Meeting of the American College of Cardiology in Orlando, Florida. March 2018
* Award for Gratitude and Appreciation for Participation for Cardiovascular Disease Prevention from

Cardio Prevent Egypt Nov 2018

* CGFO Global Innovator Generations Award Dec 2018
* Award for Gratitude and Appreciation for Participation for Cardiovascular Disease Prevention from Cardio Egypt, Egyptian Society of Cardiology Feb 2019
* Award for Achievement in Cardiovascular Disease Prevention from Egyptian Ministry of Youth and Sports

Feb 2019

* Award for Gratitude and Appreciation for Participation for Cardiovascular Disease Prevention from Aswan Heart Centre and Magdi Yacoub Heart Foundation Feb 2019
* Award for Gratitude and Appreciation for Participation for Cardiovascular Disease Prevention from The National Training Institute, Cairo-Egypt April 2019
* Distinguished Speaker from Alexandria University, Alexandria-Egypt April 2019
* Award from The Egyptian National Center for Research for Role and Contributions in Cardiovascular Prevention, Cairo, Egypt Nov 2019
* Doctor of Distinction 2022 Sarasota Scene Magazine January 2022
* Lifetime Achievement Award City of Sarasota for Medical Service over 47 years February 4, 2022
* Dr. El Shahawy Day February 4, 2022 by City of Sarasota Mayor February 4, 2022

**OTHER HONORS:**

* Naming of Patient Room Cardiac Floor at Heart and Vascular Tower University of Florida March 5, 2022
* Nomination for The American College of Cardiology (ACC) 2019 International Service Award 2018
* Nominated for the Board for Trustees from the American College of Cardiology(ACC) 2016
* Naming of Patient Room Cardiac Floor at Sarasota Memorial Hospital 2013
* National Medical Association [NMA] Fourth Annual Cobb Health Institute AWARD Jan 2010
* Honorary Life Membership in the Florida Medical Association (FMA), for 35 years of dedicated medical service in the State of Florida, presented by the FMA President. Mar 2008
* City of Sarasota Mayor Citation and Proclamation in recognition for Local, National and International Medical Education, presented by Mayor LuAnn Palmer at SMH 4th Annual Cardiovascular Symposium Feb 2008
* Selected as one of the America’s Top Cardiologist for 2007 by Consumer Research Council of America

2007

* Life Membership Award in the Sarasota County Medical Society, Sarasota, Florida Nov 2007
* Recognition Award for Dr. Shahawy 20 years Directorship of the Annual Cardiac Symposium
* Presented at the conclusion of the 20th Annual Symposium by the faculty and attendee in Agra, India
* Nov 2007
* Florida Medical Association Certificate of Recognition “A Physician Who Cares” Dec 2006
* Selected as one of the America’s Top Physicians for 2006 by Consumer Research Council of America 2006
* Chairman AHA Heart Ball Sarasota-Manatee Feb 2005
* Nomination for Physician of the Year at Doctors Hospital of Sarasota Apr 2003
* National Leadership Award by The National Republican Congressional Committee as Honorary Co-chairman of the Physician’s Advisory Board in Florida Nov 2002
* Nomination for Physician of the Year by the National Republican Congressional Committee Physician Advisory Board 2002
* Who’s Who in Medicine and Healthcare 4th Edition Marquis Who’s Who 2002-2003
* Member of the International Organizing Committee for the Golden Jubilee Congress of the Egyptian

Society of Cardiology Feb 2001

* Member Who’s Who in Executives and Businesses 2000
* A Resolution of Sarasota County Public Hospital Board 1992
* Award “Best Intern” from Flushing Hospital and Medical Center Alumni, New York 1968
* U.A.R. Scholarship for Post-Grad Training at the Vienna Academy of Medicine, Austria 1962-1967

**PUBLICATIONS**

**M.S. THESIS:** Master of Science in Medicine and Cardiovascular Diseases, University of Minnesota,

**Mayo Clinic, 1971:** **“The Role of Magnesium Deficiency in Thyrocardiac Disorders”**

**Papers Published:**

**El Shahawy et al., Egyptian Heart Journal, Excess Epicardial Fat Volume in Women is a novel risk marker for microvascular dysfunction, which may be a contributing marker in the atypical chest Syndrome. 2021 Dec; 73:37.**

**El Shahawy et al, Annals of the Heart. Early Detect to Protect: Excess Epicardial Fat Volume is a Risk Marker for Cardiovascular Health Assessment. August 9 2021.**

**El Shahawy et al., Medrxiv. Quantification of Epicardial Fat Volume as a Novel Cardiovascular Risk Marker in Asymptomatic Subjects for Early Detection of Cardiovascular Disease. June 28, 2014.**

**Cohn JN and El Shahawy M. Monitoring Cardiovascular Disease Progression. Open J Cardiol Heart Dis.3(1). OJCHD.000552.2019 August 28, 2019**

**Most recent [September 2017 article where Dr. Shahawy was the lead author along with 8 of the most renowned international professors in cardiology including Professor Christopher Canon from Harvard university published in the American Journal of cardiology on September 15, 2017,** **Volume 120, Issue 6, Pages 931-939** Efficacy and Safety of Alirocumab versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II) Mahfouz El Shahawy

**Other Publications:**

1. **M. El Shahawy, M.D.,** Early Detect to Protect: Excess Epicardial Fat Volume is a Risk Marker for Cardiovascular Health Assessment. August 9, 2021. Ann heart 5(1):123-131.
2. **M. El Shahawy, M.D.,** Excess Epicardial Fat Volume in Post-Menopausal Women is Associated with Increased Cardiovascular Structural and Functional Abnormalities.

DOI: <https://doi.org/10.1016/j.jcct.2021.06.250>.

1. **M. El Shahawy, MD, et al** “Excess Epicardial Fat Volume Regardless of a Low Coronary Artery Calcium Score is associated with Higher Cardiovascular Risk: Time to Assess Epicardial Fat Volume in All Cardiac CT Scans.[J Am Coll Cardiol](https://www.jacc.org/journal/jacc). 2021 May, 77 (18\_Supplement\_1) 1491
2. **M. El Shahawy, M.D.,** Excess Epicardial Fat Volume in Women is a Novel Risk Marker for Microvascular Dysfunction Which May Be a Contributing Factor in the Atypical Chest Pain Syndrome. Egypt Heart J. 2021 Apr 13;73(1):37. Doi: 10.1186/s43044-021-00159-4. PMID: 33847857;PMCID: PMC8044276.
3. **M. El Shahawy, M.D.,** “Epicardial Adiposity Is a Gender-biased Risk Marker For Cerebrovascular And Coronary Artery Disease In Asymptomatic Obese Subject”, Journal of Cardiovascular Computed Tomography, July 2020.
4. **M. El Shahawy, M.D.,** “Quantification of Epicardial Fat Volume as a Novel Cardiovascular Risk Marker in Asymptomatic Subjects for Early Detection of Cardiovascular Disease”, medRxiv 2020.06.28.20141622;doi:https://doi.org/10.1101/2020.06.28.20141622
5. **M. El Shahawy, MD,** Recommendations for Your Good Health: Coronavirus (COVID-19) and Cardiovascular Health, various publications, May 2020 in Sarasota, FL
6. **M. El Shahawy, MD,** Calcium Scoring and Cardiac Adipose Tissue: Novel Imaging Markers for Risk Stratification, Newsletter CardioEgypt 2020 February 26, 2020
7. **M. El Shahawy, MD**, Understanding Heart Rate and Health, Your Observer February 21, 2019
8. **M. El Shahawy**, et.al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine. September 28, 2017. DOI: 10.1056/NEJMoa1612917
9. **M. El Shahawy**, et.al. for the ODYSSEY OUTCOMES II Investigators Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II) at American Journal of Cardiology September 15, 2017, Volume 120, Issue 6, Pages 931–93
10. Milton Packer, John JV McMurray, **M. El Shahawy**, et.al. “Long-Term Effect of Endothelin Receptor Antagonism with Bosentan on the Morbidity and Mortality of Patients with Severe Chronic Heart Failure”, Journal of American College of Cardiology: Heart Failure, Vol. 5, No. 5, 317-326, May 2017. DOI: 10.1016/j.jchf.2017.02.021
11. **M. El Shahawy, MD, et al** “Increased Diastolic Blood Pressure Post-mild Exercise is Associated With Early Structural and Functional Cardiovascular Abnormalities”

14 Sep 2017<https://doi.org/10.1161/hyp.70.suppl_1.p115>Hypertension. 2017;70:AP115

1. **M. El Shahawy, MD, et al** “Incremental Changes in Systolic Blood Pressure Post-mild Exercise, in Normotensive Subjects, is Associated With Significant Structural and Functional Cardiovascular Abnormalities” <https://doi.org/10.1161/hyp.70.suppl_1.p371>Hypertension. 2017;70:AP371
2. **M. El Shahawy, MD, et al.** “Detect to Protect: Early Detection to Ultimately Protect Against Structural and Functional Abnormalities in Untreated, Asymptomatic Subjects with Low Cardiovascular Disease Risk Score” Clinical Cardiology, Vol. 39, 6-6, September 2016.
3. **M. El Shahawy, MD, et al.** “Novel Approach for Early Assessment for Cardiovascular Disease Based on Structural and Functional Abnormalities” Clinical Cardiology, Vol. 39, 8-8, September 2016.
4. **M. El Shahawy, MD, et al.** “Obesity, Even Without Other Known Cardiovascular Risk Factors, is a Disease, Regardless of Age and Gender” Clinical Cardiology, Vol. 39, 11-12, September 2016.
5. **M. El Shahawy, MD, et al.** “A Novel Test for Early Detection of Structural and Functional Cardiovascular Abnormalities in Untreated, Asymptomatic, Obese Females, Vol. 39, 17-17, September 2016.
6. **M. El Shahawy, MD**, “The Changing Landscape for Stroke Prevention in AF.” Journal of the American College of Cardiology 69(7):777-785
7. **M. El Shahawy, MD,** et al. “Prevalence of Cardiovascular Risk Factors in Asymptomatic Subjects with No Evidence of Structural and Functional Abnormalities as Assessed The Early Cardiovascular Disease Risk Score (aka Rasmussen Risk Score)” Clinical Cardiology, Vol. 38, 17-17, August 2015.
8. J.G. Robinson, **M. El Shahawy**, et.al. for the ODYSSEY LONG TERM Investigators. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. March 15, 2015, at NEJM.org DOI:10.1056/NEJMoa1501031
9. **M. El Shahawy, MD, et al**  “Is Brain Natriuretic Peptide or Pro- Brain Natriuretic Peptide of value for Early Cardiovascular Disease Risk Stratification in asymptomatic Subjects?” <https://doi.org/10.1161/circ.129.suppl_1.p352>Circulation. 2014;129:AP352
10. **M. El Shahawy, MD, et al** “Abnormal BNP in asymptomatic well controlled hypertensive subjects is a novel marker associated with early cardiovascular structural abnormalities, i.e. left ventricular hypertrophy” April 2014 [Journal of the American Society of Hypertension](https://www.researchgate.net/journal/Journal-of-the-American-Society-of-Hypertension-1933-1711) 8(4):e119 DOI:[10.1016/j.jash.2014.03.270](http://dx.doi.org/10.1016/j.jash.2014.03.270)
11. **M. El Shahawy, MD, et al “**Obesity Even Without Co-morbidity Harbors more Cardiovascular Structural and Functional Abnormalities than what you think! Time for Early CV Screening!” <https://doi.org/10.1161/circoutcomes.5.suppl_1.A276>Circulation: Cardiovascular Quality and Outcomes. 2012;5:A276
12. **M. El Shahawy, MD, et al.** “OP005 CVD Risk Assessment in Male Population Beyond Framingham” International Journal of Cardiology, Vol. 140, 2010. DOI: 10.1016/s0167-5273(10)70008-5, April 2010.
13. Effect of Niacin Extended Release and Lovastatin tablets on Jan 17, 2009, **Mahfouz El Shahawy, MD**, Principal Investigator. Your Integrative Health and Wellness Resource for Walking Success Stories. July 12, 2009.
14. Achieving Low-Density Lipoprotein Cholesterol Goals in High-Risk Patients in Managed Care: Comparison of Rosuvastatin, Atorvastatin, and Simvastatin in the SOLAR trial- William Insull, Jr, MD, Jalal K. Ghali, MD, David R. Hassman, DO, Joseph W. Ycas, PhD, Sanjay K. Gandhi, Mayo Clinic Proceedings May 2007 vol. 82 no. 5, 543-550.
15. Efficacy and Safety of Darusentan in Patients with Resistant Hypertension: Results from a Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study. Henry R Black, George L Bakris , Michael A Weber , Robert Weiss , **Mahfouz El Shahawy** , Richard Marple , Georges Tannoury , Stuart Linas , Brian L Wiens , Jennifer V Linseman , Robert Roden , Michael J Gerber. J Clin Hypertens (Greenwich). 2007 Oct 9 (10):760-769 17917503.
16. Metabolic Effects of Carvedilol vs Metoprolol in Patients ...Early Release Article **Mahfouz El Shahawy, M.D.,** (Sarasota), supported in part by a National Institutes of Health JAMA November 2004.
17. A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients with Coronary Artery Disease The International Verapamil-Trandolopril Study (INVEST): A Randomized Controlled Trial for the INVEST Investigators JAMA. 2003; 290:2805-2816.
18. “AFFIRM” investigators, et al…**M. El Shahawy, M.D.,** “A comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation” New England Journal of Medicine, Vol.347, No.23. Dec 5, 2002.
19. Barry M. Brenner, et al… **M. El Shahawy, M.D.,** “The losartan renal protection study – rationale study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) Journal of the Renin Angiotensin Aldosterone System Vol. 1, No. 4 December 2000.(Pages 328-335).
20. Roger M. Mills, MD, et al… **M. El Shahawy, M.D.,** “Sustained Hemodynamic Effects of n Infusion of Nesiritide (Human b-Type Natriuretic Peptide) in Heart Failure”, A randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of the American College of Cardiology, Vol. 34, No. 1, 1999, ISSN 0735-1097/99.
21. Bjorn Fagerber, M.D., et al… **M. El Shahawy, M.D.,** "Effect of Metoprolol CR/XL in Chronic Heart

Failure: Metoprolol CR/XL Randomized Intervention Trial In Congestive Heart Failure (MERIT-HF),

The Lancet. Saturday June 12, 1999. Vol. 353, No. 9169

1. Henry R. Black, MD, et al... **M. El Shahawy, M.D.,** "Rationale and Design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial"; Controlled Clinical Trials 19:370-390 (1998).
2. John O. Parker, M.D., et al... **M. El Shahawy, MD.,** (Minitran Clinical Study Center); "Intermittent Trans-dermal Nitroglycerin Therapy in Angina Pectoris"; Circulation, Vol. 91, No. 5, Pages 1368-1374, March 1995.
3. **M. El Shahawy, M.D.,** R.M. Tucker, H.W. Warner, R.E. Smith; "Hyperthyroidism and Potassium" (Letter to the Editor); J.A.M.A.; 217: 969.
4. M.A. Stefadouros, M.D., **M. El Shahawy, MD.,** and A. Calhoun Witham, M.D.; "Soschin in Georgia: A Case of Acute Fulminant Cardiac Beri-Beri."; J. Medical Association Georgia; 56: 149, 1976.
5. **M. El Shahawy, M.D.,** R. Graybeal, M.D., C.J. Pepin, M.D., and C.R. Conti, M.D.; "Aortic Valve Prolapse-Diagnosis by Echocardiography"; Chest, March 1976.
6. M.A. Stefadouros, M.D., **M. El Shahawy, M.D.,** F. Stefadouros, B.S., and A.C. Witham, M.D.; "The Effect of Upright Tilt on the Volume of the Failing Human Left Ventricle”; American Heart Journal, December 1975.
7. **M. El Shahawy, M.D.,** N.A. Stefadouros, M.D., A.A. Carr, and C.R. Conti, M.D.; "Direct Effect of Thyroid Hormone on Intracardiac Conduction in Acute and Chronic Hyperthyroid Animals"; Cardiovascular Research Journal, 9(4)-524-531, 1975.
8. M.A. Stefadouros, M.D., W. Grossman, M.D., **M. El Shahawy, M.D.,** F. Stefadouros, and A. Calhoun

Witham, M.D.; "Non-invasive Study of the Effect of Isometric Exercise on Left Ventricular Performance in

Normal Man"; British Heart Journal, Vol. 36: 988-995, 1974. Hyer

1. **M. El Shahawy, M.D.,** and L. Crevasse, M.D.; "Echocardiography"; Journal of Florida Medical Association, Vol. 61: 699-702, 1974.
2. M.A. Stefadouros, M.D., W. Grossman, M.D., **M. El Shahawy, M.D.,** and A.C. Witham,M.D.; "The Effect of Isometric Exercise on Left Ventricular Volume in Normal Man"; Circulation V, XLIX: 1185-1189, June 1974.
3. **M. El Shahawy, M.D.,** R.D. Smith, 1973, D.A. Scholz, and K.G. Wakim; "Magnesium Deficiency and the Hyperthyroid Heart"; Published in the Communication of the First International Symposium on Magnesium in Human Pathology, Pages 485-489, 1973 (Imp.-Amelot, France).
4. **M. El Shahawy, M.D.,** and N.C. Flowers, M.D.; "Unexplained Fever and Chills Associated with Myocardial Infarction"; 1972, Chest Volume 62, No. 3: 263-265.
5. **M. El Shahawy, M.D.,** et al… "Selected Observations Hyperthyroid, Magnesium-Deficient Dogs, The Clinic Bulletin, Vol. 49, No. 16, April 16, 1971. doi: 10.1001/jama.1971.03190070077036.
6. **M. El Shahawy, M.D.,** “Hyperthyroidism and Potassium” 1971 Aug 16;217(7):969.
7. **M. El Shahawy, M.D.,** “Role of Magnesium in Myocardial Function”, New England Journal of Medicine, Vol. 286, No. 4: 217-218, February 1971.
8. **M. El Shahawy, M.D.,** "The Effect of Magnesium Deficiency on the Cardiovascular System", Physiology, The Clinic Bulletin, Vol. 49, No. 7, February 12, 1971.

**Published Abstracts with Original Observations:**

1. El Shahawy, M., Time to Look for Epicardial Fat Volume Assessment Beyond Calcium Score. To be presented at SCCT 2024, held July 18-21, 2024. Washington, D.C.
2. El Shahawy, M., Beyond Calcium Score: Is Non-HDL Cholesterol the Next Frontier in Cardiovascular Risk Assessment? To be presented at SCCT 2024, held July 18-21, 2024. Washington, D.C.
3. El Shahawy, M., Is Cardio-obesity Associated with Elevated Non-HDL Cholesterol Levels? Is This Elevation in Non-HDL Cholesterol the Contributing Factor For Cardiovascular Risk Associated With Cardioobesity? To be presented at SCCT 2024, held July 18-21, 2024. Washington, D.C.
4. El Shahawy, M., [Lack of abnormal rise in blood pressure in obese subjects is associated with less structural and functional cardiovascular abnormalities](javascript:__doPostBack('ctl00$MainContent$MyAbstracts$abstractRepeater$ctl02$linkAbstract','')). Presented at ESC Preventive Cardiology 2024 held April 25-27, 2024. Athens, Greece.

# El Shahawy, M., Is Excess Epicardial Fat in The Presence of Elevated Calcium Score Levels the Predominant Early Contributor to Subclinical Inflammation Phenotyping into ECG Abnormalities? Presented at 84th Italian Society of Cardiology National Congress held December 14-17, 2023. Verona, Italy.

# El Shahawy, M., Low Precordial QRS Voltage as A Potential Biomarker of Cardio-Obesity. Presented at 84th Italian Society of Cardiology National Congress held December 14-17, 2023. Verona, Italy.

# El Shahawy, M., Beyond Coronary Artery Calcium Score: Epicardial Fat Volume in Cardiovascular Risk Stratification. Presented at 84th Italian Society of Cardiology National Congress held December 14-17, 2023. Verona, Italy.

1. El Shahawy, M., Epicardial Fat Volume as a Novel Risk Marker for Cardiovascular Risk Assessment Beyond Coronary Artery Calcium Score. Presented at SCCT 2023 held July 27-30. Boston, MA.
2. El Shahawy, M., Excess Epicardial Fat Volume is a Novel Risk Marker for Early Cardiovascular Disease Risk Assessment in Prediabetes Beyond Calcium Scores. Presented at SCCT 2023 held July 27-30, 2023. Boston, MA.
3. El Shahawy, M., Abdominal Visceral and or Cardiac Adiposity in Young Adults is Associated with Significant Subclinical Metabolic and Cardiovascular Structural and Functional Abnormalities. Presented at ASPC 2023 held July 21-23, 2023. Arlington, TX
4. El Shahawy, M., Is elevated calcium score alone or with the additional contribution of excess epicardial fat the trigger causing early inflammation leading to ECG abnormalities? ESC-EHRA 2023 held April 16-18, 2023. Barcelona, Spain
5. El Shahawy, M., Pre-Diabetes in Assymptomatic Subjects Mandates Early Screening for Cardiovascular Abnormalities and Risk Stratification for Appropriate Treatment. Presented at American College of Cardiology. ACC.23 WCC held March 4-6, 2023. New Orleans, LA.
6. El Shahawy, M., Is low voltage QRS ECG a possible marker for cardio obesity? CardioEgypt held February 21-23, 2023. Cairo, Egypt.
7. El Shahawy, M., Does the assessment of Epicardial Fat Volume further optimize cardiovascular risk stratification beyond Coronary Artery Calcium Score? CardioEgypt held February 21-23, 2023. Cairo, Egypt.
8. El Shahawy, M., Pre-Diabetes is Prevalent and Associated with Subclinical Cardiovascular Abnormalities. Is There a Gender Difference? CardioEgypt held February 2023, Il Cairo, Egypt
9. El Shahawy M., Novel Approach for Optimal Assessment of Cardiovascular Risk of Blood Pressure in Asymptomatic Subjects Utilizing Mild Exercise Stress Test Protocol. Presented at the American Heart Association AHA22 held November 5-7, 2022. Chicago, IL.
10. El Shahawy M., The Abnormal Rise in Both Sysolic and Diastolic Blood Pressure Post-mild Exercise Protocol Associated with More Cardiovascular Structural and Functional Abnormalities Than Isolated Systolic or Diastolic Rise Alone? Presented at the American Heart Association AHA22 held November 5-7, 2022. Chicago, IL.
11. El Shahawy M., Prediabetes is prevalent and Frequently Associated with Subclinical Cardiovascular Abnormalities. Is There A Gender Difference? Presented at the American College of Cardiology ACC22 held April 2-4, 2022. Washington DC.
12. El Shahawy M. (2021), Excess Epicardial Fat Volume as a Novel Risk Marker for Cardiovascular structural and functional abnormalities including Arrythmia/Atrial Fibrillation-Enhancing Risk Factors: Novel Data From Our Cardiovascular Center In Sarasota, Florida, DoloMeeting Arrhythmias, Bolzano, Italy - March 10, 2022
13. El Shahawy M., Excess Epicardial Fat Volume is a Novel Risk Marker for Cardiovascular Disease Risk Assessment Beyond Coronary Artery Calcium Score. Presented at American Heart Association Annual Scientific Sessions held Nov. 13-15, 2021, Boston, Massachusetts.
14. El Shahawy M., Epicardial Fat Volume as a Novel Risk Marker for Cardiovascular Disease Risk Assessment Beyond Coronary Artery Calcium Score. Presented at Florida Medical Association Annual Meeting July 2021, Orlando, Florida.
15. El Shahawy M., Defining the Low-Risk Values for Epicardial Fat Volume as a Marker for Cardiovascular Disease Risk. Presented at Florida Medical Association Annual Meeting July 2021, Orlando, Florida.
16. El Shahawy M., Excess Epicardial Fat Volume in Post-Menopausal Women is a Novel Cardiovascular Risk Marker. Presented at SCCT July 16-17, 2021.
17. El Shahawy M., A Stepwise Increase in Epicardial Fat Volume is Associated with Increased Microvascular and Macrovascular abnormalities. Presented at SCCT July 16-17, 2021.
18. El Shahawy M., Excess Epicardial Fat Volume Despite Low or Zero Coronary Artery Calcium Score Correlates Well with Increased Risk for Cardiovascular Disease. Presented at ACC 70th Annual Scientific Session, Virtual May 15-17, 2021.
19. El Shahawy M., A Stepwise Increase in Epicardial Fat Volume is Associated with Increased Prevalence of ECG Abnormalities: Time to Assess EFV as a Significant Risk Marker for Possible Arrhythmias. Presented CardioEgypt 48th International Congress, Egyptian Society of Cardiology, II Cairo, Egypt Feb 15-18, 2021.
20. El Shahawy M., A Stepwise Increase in Epicardial Fat Volume is Associated with Increased Microvascular Abnormalities: Time to Assess EFV as a Significant Risk Marker for Early CVD Detection, Presented at CardioEgypt 48th International Congress, Egyptian Society of Cardiology, II Cairo, Egypt

Feb 15-18, 2021.

1. El Shahawy M., Excess Epicardial Fat Volume is a Significant Risk Marker for Metabolic Syndrome, including HDL levels. Presented at CardioEgypt 48th International Congress, Egyptian Society of Cardiology, II Cairo, Egypt Feb 15-18, 2021.
2. El Shahawy M., Hypertriglyceridemia in Asymptomatic Obese Subjects Without Other Comorbidities is Associated with Significant Structural and Functional Abnormalities as Compared with Control, Presented at 81° Congresso Nazionale SIC - Società Italiana di Cardiologia – Roma/Virtual, December 17-20, 2020
3. El Shahawy M., Excess Epicardial Fat Volume as a Novel Risk Factor for CV Structural and Functional Abnormalities, Presented at 81° Congresso Nazionale SIC - Società Italiana di Cardiologia – Roma/Virtual, December 17-20, 2020
4. M. El Shahawy, MD, “Excess Epicardial Fat Volume Is Associated with Increased Cardiovascular Structural and Functional Abnormalities In Menopausal Women Regardless Of Body Weight: The Higher The Epicardial Fat Volume, The Higher The Abnormalities”, presented at AHA20 Scientific Sessions, November 13-17, 2020 in Dallas, Texas.
5. M. El Shahawy, MD, “Epicardial Adiposity is a Gender-biased Risk Marker for Cerebrovascular Coronary Artery Disease in Asymptomatic Obese Subjects”, presented at SCCT2020 July 16-19, 2020, in Seattle, Washington.
6. M. El Shahawy, M.D.,“Epicardial Adiposity Is a Gender-biased Risk Marker For Cerebrovascular And Coronary Artery Disease In Asymptomatic Obese Subjects presented July 17-18, 2020 in Washington, DC
7. M. El Shahawy, MD, “Hypertriglyceridemia in Asymptomatic Obese Subjects Without Other Comorbidities is Associated with Significant Structural and Functional Abnormalities as Compared with Control” presented at ESC Preventive Cardiology 2020 Malaga, Spain, April 2020.
8. El Shahawy M., Abnormal Epicardial Fat Volume as the Driving Force Contributing to Structural and Functional Abnormalities Even with Normal Calcium Score in a 10-year Follow-up Health Assessment Program in the Sarasota, FL Community, presented at the 2020 ESC-Europrevent Conference, April 2-4, 2020, Malaga, Spain
9. M. El Shahawy, MD: “Excess Epicardial Fat Volume as a Novel Cardiovascular Disease Risk Factor Even in Non-Obese Asymptomatic Subjects”, Presented at ESC-Europrevent 2019, April 11-13, 2019, Lisbon, Portugal
10. M. El Shahawy, MD “Obese Subjects with Excess Epicardial Fat Volume have Significant CV Structural and Functional Abnormalities as compared to Obese Subjects with Normal Epicardial Fat Volume”, presented at World Congress of Cardiology and Cardiovascular Health 2018, Dubai, United Arab Emirates, December 5-8, 2018
11. M. El Shahawy, MD, “Cardio-Obesity/Excess Epicardial Fat Volume is Associated with Significant CV Structural and Functional Abnormalities in Asymptomatic non-Obese subjects”, presented at World Congress of Cardiology and Cardiovascular Health 2018, Dubai, United Arab Emirates,

December 5-8, 2018

1. M. El Shahawy, MD, “Excess Epicardial Fat Volume in Non-Obese Subjects is a Major CV Risk Factor for Micro and Macro Vascular Abnormalities”, presented at World Congress of Cardiology and Cardiovascular Health 2018, Dubai, United Arab Emirates, December 5-8, 2018
2. M. El Shahawy, MD, “The Obesity Paradox: is the Lack of Excess Epicardial Adipose Tissue Partially or Totally the Answer for the Enigma?” Presented at 2018 CardioPrevent, November 15-16, 2018,

Cairo, Egypt.

1. M. El Shahawy, MD; “Non-Obese and Obese Subjects Without Excessive Epicardial Fat Volume Have Less CV Structural and Functional Abnormalities”, Presented at 2018 CardioPrevent, November 15-16, 2018, Cairo, Egypt
2. M. El Shahawy, MD.: “Hypertriglyceridemia in Asymptomatic Subjects is an Early Indicator for Cardiovascular Structural and Functional Abnormalities” Presented at the ESC-Europrevent 2018, Annual Scientific Meeting, April 19-21, 2018, in Ljubljana, Slovenia
3. M. El Shahawy, MD, “hsCRP and pro-BNP: Markers for Early Cardiovascular Structural and

Functional Abnormalities in Asymptomatic Subjects?” Presented at the American Society for Preventive Cardiology 2017 Congress, September 15-17, 2017, Fort Lauderdale, Florida, FL

1. M. El Shahawy, M.D. et al. “Excess Epicardial Fat is Associated with Early Structural and Functional Cardiovascular Abnormalities.” Presented at 2017 12th Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography.
2. M. El Shahawy, M.D. et al. “Excess Epicardial Fat Is Associated With an Abnormal Rise in Systolic Blood Pressure Post-Exercise in Asymptomatic and Untreated Subjects.” Presented at 2017 12th Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography, 2017.
3. M. El Shahawy, MD, “Routine ECG in Asymptomatic Subjects Might be a Clue for Early Cardiovascular Structural and Functional Abnormalities”, presented at the ESC, EHRA, Europace, Cardiostim Conference,

June 18-21, 2017.

1. M. El Shahawy, MD, “Decades of Obesity Even Without Comorbidities in Asymptomatic Subjects is Associated with Significant Cardiovascular Structural and Functional Abnormalities,” Presented at the European Society of Cardiology Europrevent 2017 Conference, April 6 - 8, 2017, Malaga, Spain.
2. M. El Shahawy, MD, “Epicardial Adiposity, Regardless of Visceral Adiposity, is Associated with Significant Cardiovascular Abnormalities in Untreated and Asymptomatic Subjects, as Measured by the Calcium Score,” Presented at the European Society of Cardiology Europrevent 2017 Conference, April 6-8, 2017, Malaga, Spain.
3. M. El Shahawy, MD: “A Resting Blood Pressure Greater Than 130/80 mmHg Correlates with an Increase in Early Structural and Functional Abnormalities—Time to Reevaluate the Current Standards of Care,” Presented at the American Heart Association 2016 Scientific Sessions, November 13-15, 2016, New Orleans, LA.
4. M. El Shahawy, MD, “Early Structural and Functional Cardiovascular Abnormalities in Asymptomatic Subjects—More Common than One Would Expect,” Presented at the American Society for Preventive Cardiology 2016 Congress on Atherosclerotic Cardiovascular Disease Prevention, September 16-18, 2016, Boca Raton, FL.
5. M. El Shahawy, MD, “Time to Retire BMI: An Assessment of Body Mass Index and Waist Circumference as Predictors for Structural and Functional Cardiovascular Abnormalities,” Presented at the American Society for Preventive Cardiology 2016 Congress on Atherosclerotic Cardiovascular Disease Prevention, September 16-18, 2016, Boca Raton, FL.
6. M. El Shahawy, M.D. et al. “Obesity, Even Without Other Known Cardiovascular Risk Factors, is a Disease, Regardless of Age and Gender.” Presented at the 2016 Congress on atherosclerotic cardiovascular disease prevention, September 16- 18, 2016, Boca Raton, FL.
7. M. El Shahawy, MD: “Waist to Height Ratio as a Predictor of Early Structural and Functional Cardiovascular Abnormalities in Untreated and Asymptomatic Subjects,” Presented at the American Society for Preventive Cardiology 2016 Congress on Atherosclerotic Cardiovascular Disease Prevention, September 16-18, 2016, Boca Raton, FL.
8. M. El Shahawy, M.D. et al.: Abnormal Rise in Blood Pressure Post Mild Exercise is a Marker for Early Cardiovascular Disease Beyond Framingham and AHA-ACC 10Y-ASCVD Risk Scores, Presented at the ESC Conference, Rome, Italy, Aug 27-31, 2016
9. M. El Shahawy, M.D. et al.: Novel Markers and Tools for Early Assessment of CV Risk Beyond Framingham and ACC/AHA Guidelines
10. M. El Shahawy, M.D. et al.: Efficacy and Safety of Alirocumab Versus Ezetimibe Over 104 Weeks in Patients with Hypercholesterolemia and High Cardiovascular Risk: Final Results From Odyssey Combo II, Presented at the National Lipid Association in New Orleans for the 2016 Scientific Sessions, May 19-22, 2016
11. M. El Shahawy, M.D. et al.: Abnormal Rise in BP is Associated with Increased Prevalence of LVH Even in Asymptomatic Pre-Hypertensive Subjects, Presented at the ESC Heart Failure Conference, Florence, Italy, May 21-24, 2016
12. M. El Shahawy, M.D. et al.: Incremental Rise in Blood Pressure from Normotensive to Hypertensive is a Major Risk Factor for LVH, Presented at the ESC Heart Failure Conference, Florence, Italy, May 21-24, 2016
13. M. El Shahawy, M.D. et al.: Silent Hypertension in Normotensive Subjects is a Major Risk Factor for LVH, Presented at the ESC Heart Failure Conference, Florence, Italy, May 21-24, 2016
14. M. El Shahawy, M.D. et al.: Pre-hypertension/Hypertension Update 2016: How Low Should We Go?, Presented at the American Society of Hypertension 2016 Annual Scientific Meeting, at the Hilton NY, NYC, May 13-17, 2016
15. M. El Shahawy, M.D. et al.: “Abnormal Rise in Blood Pressure Post Mild Exercise Protocol as a Novel Risk Marker for Early CVD Risk Assessment” - presented at the 2015 American Society for Preventive Cardiology - Cardiovascular Disease Conference July 31–August 2, 2015, Boca Raton Resort & Club, Florida; 08/2015
16. M. El Shahawy, M.D. et al: “Abnormal Rise in Blood Pressure Post Mild Exercise as a Novel Tool for CV Risk Stratification in Asymptomatic Subjects” - presented at Annual Meeting of American Society of Hypertension, May 16, 2015, in New York, New York.
17. M. El Shahawy, M.D. et al.: “AHA/ACC Pooled-Cohort Equations to Estimate 10-year Atherosclerotic Cardiovascular Disease (ASCVD) Risk vs. Early/current Cardiovascular Disease Risk Score (ECVDRS), an Evidence Based Medicine Risk Scoring System” - presented at EuroPrevent, May 15, 2015 in Lisbon, Portugal
18. M. El Shahawy, M.D. et al.: “Long-term Safety, Tolerability and Efficacy of Alirocumab Versus Placebo in High Cardiovascular Risk Patient: First Results from the ODYSSEY LONG TERM Study in 2,341   
    Patients” – presented at American College of Cardiology Annual Meeting, March 2015 in New York, New York.
19. M. El Shahawy, M.D. et al.: “Abnormal Rise in Blood Pressure Post Exercise in Asymptomatic Normotensive Subjects is Associated with Structural and Functional Cardiovascular Abnormalities” - presented at European Society of Cardiology 2014 Annual Meeting, 30 Aug 2014 - 03 Sep 2014, Barcelona, Spain, Europe.
20. M. El Shahawy, M.D. et al.: “Triglyceride-to-HDL Cholesterol Ratio in Asymptomatic Subjects Is Associated with Structural and Functional Cardiovascular Abnormalities” - presented at the 9th Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography, July 12, 2014, San Diego, California.
21. M. El Shahawy, M.D. et al.: “Abnormal Triglyceride to HDL Ratio is Associated with Significant Subclinical Atherosclerosis as Evidenced by Abnormal Coronary Calcium Score.” - presented at the 9th

Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography, July 12, 2014, San Diego, California

1. M. El Shahawy, M.D. et al.: “Abnormal BNP in Asymptomatic Well Controlled Hypertensive Subjects is a Novel Marker Associated with Early Cardiovascular Structural Abnormalities, i.e. Left Ventricular Hypertrophy” –presented at the annual meeting of the American Society of Hypertension (ASH), New York, NY, and May 2014.
2. M. El Shahawy, M.D. et al.: “Smoking Even without Comorbidities Is a Major Risk Factor for Early Cardiovascular Structural and Functional Abnormalities” – presented at the World Congress of Cardiology Scientific Sessions, Melbourne, Australia, and May 7, 2014.
3. M. El Shahawy, M.D. et al.: “Is Low HDL a Risk Factor for Cardiovascular Disease?” – presented at the World Congress of Cardiology Scientific Sessions 2014, Melbourne, Australia, and May 6, 2014.
4. M. El Shahawy, M.D. et al.: “B-type Natriuretic Peptide (BNP) as a Novel Bio-marker for Left Ventricular Hypertrophy in Asymptomatic, Uncontrolled Hypertensive Subjects” – presented at the ESC Euro Prevent 2014 Scientific Sessions, Amsterdam, Netherlands, Europe, May 8-10, 2014
5. M. El Shahawy, M.D. et al.: “Abnormal Blood Pressure Rise Post Mild Exercise and Abnormal B-type Natriuretic Peptide (BNP) or NT pro-BNP are Markers for Early Cardiovascular Disease Risk Stratification in Asymptomatic Subjects” – presented at the ESC Euro Prevent 2014 Scientific Sessions, Amsterdam, Netherlands, Europe, May 8-10, 2014.
6. M. El Shahawy, M.D. et al.: “BNP as a Marker for Left Ventricular Hypertrophy in Asymptomatic, Normotensive Individuals” –presented at the ACC Annual Scientific meeting, Chicago, Illinois, March 2014.
7. M. El Shahawy, M.D. et al.: “Calcium Score vs. CRP and for Early Cardiovascular Disease Risk Stratification- Which test to choose?” – presented at the SCCT Hawaii Scientific Meeting, Waikoloa, The Island of Hawaii, and January 16, 2014.
8. M. El Shahawy, M.D. et al.: “Pre-diabetes is a Disease Associated with Significant Cerebrovascular and Cardiovascular Structural and Functional Abnormalities” – presented at the European Society of Cardiology Annual Scientific Meeting, Amsterdam, Netherlands, Europe, September 2, 2013.
9. M. El Shahawy, M.D. et al.: “Epicardial Adiposity is a Gender-Based Risk Marker for Cerebrovascular and Coronary Artery Disease in Asymptomatic Obese Subjects” – presented at the American Society of Cardiovascular Computed Tomography 8th Annual Scientific Meeting, Montreal, Canada, July 13, 2013.
10. M. El Shahawy, M.D. et al.: "Smoking is a Major Risk Factor for Structural and Functional Cerebrovascular and Cardiovascular Abnormalities"- presented at the American Society of Hypertension 28th Annual Scientific Meeting, San Francisco, California, and May 17, 2013.
11. M. El Shahawy, M.D. et al.: "Abnormal Blood Pressure Rise post Mild Exercise in a Smoker is a Clue for Early Major Cardiovascular Structural and Functional Abnormalities" - presented at the American Society of Hypertension 28th Annual Scientific Meeting, San Francisco, California, and May 16, 2013.
12. M. El Shahawy, MD et all: “Abnormal BP Rise Post Mild Exercise is a Novel Risk Stratifier Regardless of Baseline Untreated BP Level in Normotensive, Pre-hypertensive or hypertensive subjects”, presented at the European Society of Cardiology (ESC) Euro Prevent 2013 Annual Meeting scheduled for Apr. 18 – 20, 2013, in Rome - Italy
13. M. El Shahawy, M.D. et al.: "Perivascular Adipose Tissue and/or Epicardial Adiposity in Asymptomatic Obese Subjects is More Than a Scaffold: It is a Risk Marker for Cerebrovascular and Coronary Artery Disease"- presented at the AHA Epidemiology and Prevention/Nutrition, Physical Activity and Metabolism 2013 Scientific Sessions, March 19-22, 2013, New Orleans, LA.
14. M. El Shahawy, M.D. et al.: “Pre-Hypertension is a Disease Associated with Significant Structural and Functional Cardiovascular Abnormalities. It is Time to Lower the Bar.", presented at the American Heart Association High Blood Pressure Research 2012 Scientific Sessions, Washington, DC, September 22, 2012.
15. M. El Shahawy, MD, MS, FESC, FACC, FAHA, FSCC, FSCCT FASH: “Abnormal Blood Pressure Rise Post Mild Exercise Protocol in Newly Diagnosed Hypertensive Subjects is Associated with Significant

Cardiovascular Functional/Structural Abnormalities”, presented at the European Society of Cardiology Annual Scientific Meeting, August 28th, 2012, Munich, Germany.

1. M. El Shahawy, M.D. et al.: “Beware of the Presence of Coronary Artery Calcification on any Imaging Procedure!”, presented at 7th Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography, July 20, 2012, Baltimore, Maryland.
2. M. El Shahawy, M.D. et al.: “Pre-Hypertension Is a Prevalent, Unrecognized and Untreated Risk Factor for Cardiovascular Disease (CVD). Time for Paradigm Shift!” presented at the American Society of Hypertension 2012 Annual Scientific Meeting, New York, NY, and May 21st, 2012.
3. M. El Shahawy, M.D. et al.: “Cardiovascular Disease Is The Number One Killer In The United States. It Is Time To Look Beyond Framingham Risk Score For Alternative 21st Century Risk Scoring System!” presented at the American Society of Hypertension 2012 Annual Scientific Meeting, New York, NY, May 20th, 2012.
4. M. El Shahawy, M.D. et al.: “Abnormal Blood Pressure (BP) Rise Post Mild Exercise in Hypertensive Patients Is an Additive Risk Factor”, presented at the American Society of Hypertension 2012 Annual Scientific Meeting, New York, NY May 19th, 2012.
5. M. El Shahawy, M.D. et al.: “What are the early cardiovascular (CV) structural and functional abnormalities associated with obesity?”, presented at the ESC Heart Failure 2012 Congress - held in Belgrade Serbia, 19-22 May 2012.
6. M. El Shahawy, M.D. et al.: “Obesity Even Without Co-Morbidity Harbors more Cardiovascular Structural and Functional Abnormalities than what you think! Time for Early CV Screening!” presented at the Quality of Care and Outcomes Research 2012 Scientific Sessions in Atlanta, GA, May 9-11, 2012.
7. M. El Shahawy, M.D. et al.: “Obesity Even without Comorbidity Is a Risk Marker for Stroke” presented at the American Heart Association/American Stroke Association's International Stroke Conference, Feb. 1-3 in New Orleans, LA.
8. M. El Shahawy, M.D. et al.: “The Value of Optimal Blood Pressure Control in Reducing Functional and Structural Cardiovascular Abnormalities”, presented at 15th Annual Scientific Meeting of the Heart Failure Society of America, September 18-21, 2011, Boston, MA.
9. M. El Shahawy, M.D. et al.: “Obesity and cardiovascular disease (CVD): an association or a cause-and-effect relationship?”, presented at the European Society of Cardiology 2011 Annual Scientific Meeting, Paris, France, August 2011.
10. M. El Shahawy, M.D. et al.: “Is Pericardial Fat Volume Gender Specific? Is its excess a villain for Cardiovascular Disease Risk in Metabolic Syndrome subjects”, presented At the Sixth Annual Scientific Meeting of the Society for Cardiovascular Computed Tomography (SCCT), Denver, Colorado, July 2011.
11. M. El Shahawy, M.D. et al.: “Novel method for Assessing the Prevalence of Hypertension and Cardiovascular Disease Risk in a Community Screening Program in a Southeast Region of US”, Presented at the American Society of Hypertension 2001 Annual Scientific Meeting, New York, NY, May 2011.
12. M. El Shahawy, M.D. et al.: “Pre-Hypertension: is it a disease?”, presented at the American Society of Hypertension 2011 Annual Scientific Meeting, New York, NY, May 2011.
13. M. El Shahawy, M.D. et al.: “Predictors of early cardiovascular disease risk in asymptomatic Metabolic Syndrome individuals: Which test is best?”, presented at the AHA Quality Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC, May 2011.
14. M. El Shahawy, M.D. et al.: “Is Metabolic Syndrome Cardiovascular Disease (CVD) Risk Equivalent?”, Presented at the European Society of Cardiology (ESC) Euro Prevent 2011 Annual Meeting, Geneva, Switzerland, April 2011.
15. M. El Shahawy, M.D. et al.: “Abnormal Systolic Blood Pressure Rise Post Exercise as a Marker for Early Cardiovascular Disease Risk assessment in Asymptomatic Normotensive Subjects”, presented at the American College of Physicians, Florida Chapter Associate Meeting - March 11-13th, 2011, Orlando,
16. M. El Shahawy, M.D. et al.: “Value of Pro BNP as a Screening Tool for the Assessment of Early Cardiovascular Disease Risk Assessment”, presented at the American College of Physicians Florida Chapter Associate Meeting - March 11-13th, 2011, Orlando, FL.
17. M. El Shahawy, M.D. et al.: “Novel Approaches for Risk Stratification and Management of Asymptomatic Metabolic Syndrome Subjects: Is Metabolic Syndrome a Marker of Coronary Artery Disease in All?”, Presented at the Society for Cardiovascular Computed Tomography [SCCT'] Fifth Annual Scientific Meeting July 15-18, 2010.
18. M. El Shahawy, M.D. et al.: “Carotid Intima Medial Thickness (CIMT) and small artery elasticity (C2) as a powerful tool for cardiovascular disease (CVD) risk stratification as compared with high-sensitivity C-reactive protein (hCRP) regardless of sex”, Presented at the International Academy Of Cardiology 15th World Congress on Heart Disease Annual Scientific Sessions 2010, Vancouver, B.C., Canada, July 24-27, 2010.
19. M. El Shahawy, M.D. et al.: “Carotid Intima Medial Thickness (CIMT) Measurement for Cardiovascular Disease (CVD) Risk Stratification In Newly Diagnosed Asymptomatic Hypertensive Patients”, Presented at the 25th Annual American Society of Hypertension. May 1-4, 2010, New York, NY.
20. M. El Shahawy, M.D. et al.: “Rise in Systolic Blood Pressure (SBP) Over 30 mmHg After Mild Exercise as a New Marker for Early Cardiovascular Disease Risk Stratification in Asymptomatic Normotensive Patients regardless of Sex”, presented at the International Conference on Early Disease Detection and Prevention (EDDP), Munich, Germany, February 2010.
21. M. El Shahawy, M.D. et al.: “Why Early Screening For CVD Risk Stratification With A More Accurate Risk Score Method Must Be Mandated By Those Who Care About Our Health?”, presented at the International Conference on Early Disease Detection and Prevention (EDDP), Munich, Germany, February 2010.
22. M. El Shahawy, M.D. et al.: “Time to Mandate a More Accurate Tool to Assess CVD risk in Women beyond Framingham”, presented at the International Conference on Early Disease Detection and Prevention (EDDP), Munich, Germany, February 2010.
23. M. El Shahawy, M.D. et al.: “Early Cardiovascular Disease Risk Score as a More Sensitive Guide than Framingham Score for Cardiovascular Risk Prediction in Males and Its Correlation with Hypertension”, Presented at the 24th Annual American Society of Hypertension., May 6-9, 2009. San Francisco, CA.
24. M. El Shahawy, M.D., M.S., F.E.S.C., F.A.C.C., et al.: “Darusentan Antihypertensive Effect in Patients with Resistant Hypertension”, Presented at the 55th Annual Scientific Session American College of Cardiology, March 12, 2006, Atlanta, GA
25. M. El Shahawy, et. al., C.R. Conti; “Thyroid Hormone and the Prevention of Heart Block” Journal of Clinical Research, VXXIII, No. 5, BA.
26. M. El Shahawy, et. al.; “Effect of Acute Thyroid Hormone” Administration on Intracardiac Conduction. Supplement III, Circulation 49 & 50, October 1974, page 171.
27. M. E1 Shahawy, et. al.; “Magnesium Deficiency and the Thyrotoxic Heart” World Congress of Cardiology Communications, Abstract #568.
28. M. E1 Shahawy, et. al.; “L’ Effect De L’ Administration Acute De L’ Hormone Thyroidizue sur la Transmission Intra-Cardiac” World Congress of Cardiology, September 1974, Abstract #569.
29. M. El Shahawy, et. al.; “Effect of Tilt on Left Ventricular Function in Man” Circulation Supplement, October 1973, XLVIII, No. 4, October 1973, page 160.
30. M. Stefadouros, M. El Shahawy, et.al.; “Non-Invasive Study of the Effect of Isometric Exercise on the Size and Performance of the Normal Heart” Circulation Supplement, October 1973, XLVIII, No. 4, P.48.
31. M. El Shahawy, et. al.; “Fine Structural Changes in Cardiac Muscle of Hyperthyroid Dogs” Clin. Res. Vol. XXI, No. 3, April 1973.
32. M. El Shahawy, et. al.; “The Effect of Thyroid Hormone on Intracardiac Conduction in Acute and Chronic Studies” Clin. Res. Vol. XXI, No. 3, April 1973, page 416.
33. M. El Shahawy, et. al.; “The Effect of Hyperkalemia on Intracardiac Conduction in Hyperthyroid Dogs” Clin. Res., January 1973, page 36
34. Albert A. Carr, M. El Shahawy, et. al.; “The Effect of Thyroid Hormone and B-Blockade on Renin Release in Hyperthyroid Dogs” Circulation Research Supplement, October 1972, page 71.
35. M. El Shahawy, et. al.; “The Effect of Thyroid Hormone on Intracardiac Conduction with and without Propranolol” Circulation Research Supplement, October 1972, page 40.
36. M. El Shahawy, et. al.; “Effective Renin Activity in Plasma of Children with Kwashiorkor” Lancet, Vol1:1241, 1972.
37. M. El Shahawy, et. al.; “Thyroxin, Magnesium, and Lipids” Clin. Res. Vol. XX, No. 3, April 1972,P. 397.
38. M. El Shahawy, et. al.; “Magnesium Deficiency Cardiomyopathy in Hyperthyroid Dogs” Clin. Res. Vol. XX, No.3, April 1972, page 39.
39. M. El Shahawy, et. al.; “Magnesium Deficiency Cardiomyopathy in Hyperthyroid Dogs” Clin. Res. Vol. XX, No.3, April 1972, page 39.
40. M. El Shahawy, et. al.; “Increased Plasma Renin Activity and Secondary Aldosteronism in Hypothyroidism: Augmentation by Magnesium Deficiency” Circ. Res. Suppl. October 1971, page 129.
41. M. El Shahawy, et. al.; “Cardiovascular Effects of Magnesium Deficiency and Thyroxine Administration” Chest, Vol.60, September 1971, page 306. (Cecile Lehman Mayer Research)
42. M. El Shahawy, et. al.; “Magnesium Deficiency and the Hyperthyroid Heart” Summaries of Communications of First International Symposium on Magnesium Deficiency in Human Pathology, page 79, May 1971.

**Letters to the Editor:**

1. M. El Shahawy, et. al.; “Arrhythmias and the Varieties of Sleep” N.E.J.M. 282:815, April 2, 1970. (Letter to the Editor)
2. M. El Shahawy, et. al.; Hypertension and Potassium” J.A.M.A. 217:7, August 16, 1971, 969. (Letter to the Editor)

**Invited Speaker/Faculty at National Medical Meetings:**

1. Excess Epicardial Fat Volume: Novel Cardiovascular Risk Factor. Presented at the 24/24/24 24th Annual National CardioSarasota, Florida Congress for Cardiovascular Disease Prevention and Optimal Treatment Update: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association, February 2-3, 2024, in Sarasota, FL
2. Diabetes as a Major Cardiovascular/Renal Risk Factor: What to Do in 2024. Presented at the 24/24/24 24th Annual National CardioSarasota, Florida Congress for Cardiovascular Disease Prevention and Optimal Treatment Update: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association, February 2-3, 2024, in Sarasota, FL.
3. Cardio obesity as a novel risk factor. Presented at the Cardio Elite Case-Based Conference with Experts May 25-26, 2023, in Cairo, Egypt.
4. Cardio-Obesity Even Without Comorbidity is a Major Cardiovascular Risk Factor. Presented at the 23/23/23 23rd Annual National CardioSarasota, Florida Congress for Cardiovascular Disease Prevention and Optimal Treatment Update: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 3-4, 2023, in Sarasota, FL
5. Diabetes as a Major Cardiovascular/Renal Risk Factor: What to Do in 23. Presented at the 23/23/223 23rd Annual National CardioSarasota, Florida Congress for Cardiovascular Disease Prevention and Optimal Treatment Update: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 3-4, 2023, in Sarasota, FL
6. Excess Epicardial Fat Volume: Novel Cardiovascular Risk Factor. Presented at the 23/23/223 23rd Annual National CardioSarasota, Florida Congress for Cardiovascular Disease Prevention and Optimal Treatment Update: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 3-4, 2023, in Sarasota, FL
7. Obesity with and Without Comorbidities is a Disease: Novel Data from Our Center Sarasota, Florida.

Presented at the 22/22/22 22nd Annual National CardioSarasota, Florida Congress for Cardiovascular Disease Prevention and Optimal Treatment Update: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 4-5, 2022, in Sarasota, FL

1. What Should We Use Today as First Line Drug for Optimal Management of Type 2 Diabetes for Cardiovascular and Renal Protection? Presented at the 22/22/22 22nd Annual National CardioSarasota, Florida Congress for Cardiovascular Disease Prevention and Optimal Treatment Update: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 4-5, 2-22, in Sarasota, FL
2. Excess Epicardial Fat is a Risk Factor: Novel Data from Our Center. Presented at the 22/22/22 22nd Annual National CardioSarasota, Florida Congress for Cardiovascular Disease Prevention and Optimal Treatment Update: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 4-5, 2022, in Sarasota, FL
3. Excess Epicardial Fat Volume is a Novel Cardiovascular Risk Marker Associated with Structural and Functional Abnormalities- Novel Data from Our Cardiovascular Center in Sarasota, Florida. Presented at the 21/21/21 Annual National Sarasota Congress for Cardiovascular Disease Prevention and Optimal Treatment: Update 2021: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association May 28-30, 2021, in Sarasota, FL
4. Novel Approach for Primary and Secondary Prevention of Cardiovascular Disease in Diabetics. Presented at the 21/21/21 Annual National Sarasota Congress for Cardiovascular Disease Prevention and Optimal Treatment: Update 2021: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association May 28-30, 2021, in Sarasota, FL
5. Obesity With and Without Comorbidities is a Disease: Novel Data from Our Center in Sarasota, Florida. Presented at the 21/21/21 Annual National Sarasota Congress for Cardiovascular Disease Prevention and Optimal Treatment: Update 2021: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association

May 28-30, 2021, in Sarasota, FL

1. New Strategies to Manage Residual Risk Beyond Statin Therapy in Patients with or at High Risk for Cardiovascular Events, presented at Mercer Medical School March 11, 2020, in Macon, GA
2. Current Diagnosis and Management of Peripheral Arterial Disease, presented at the 20/20/20Annual National Sarasota Congress for Cardiovascular Disease Prevention Update 2020: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 7-9, 2020, in Sarasota, FL
3. Current Diagnosis and Management of Dyslipidemia Beyond Statin and PCSK9, presented at the 20/20/20Annual National Sarasota Congress for Cardiovascular Disease Prevention Update 2020: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 7-9, 2020, in Sarasota, FL
4. Obesity Even Without Comorbidities is a Disease: Novel Data from Our Center, presented at the 20/20/20Annual National Sarasota Congress for Cardiovascular Disease Prevention Update 2020: jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 7-9, 2020, in Sarasota, FL
5. New Strategies to Manage Residual Risk Beyond Statin Therapy and PCSK9 Inhibitors in Patients with or at High Risk of Cardiovascular Events presented at Sarasota Memorial Hospital jointly provided by Postgraduate Institute for Medicine and Medtelligence, October 29, 2019, in Sarasota, FL
6. Current Treatment of Dyslipidemia Beyond Statin and PCSK9 Inhibitors presented at Current Trends in Cardiovascular and Cardiometabolic Disease Prevention, and Updates in Cardiac Devices and Advanced Cardiac Failure jointly provided by the Association of Black Cardiologists, Inc. and International Society for Cardiovascular Disease Prevention (ISCVDP) October 12, 2019, in Los Angeles, CA
7. Obesity is a Major Risk Factor, presented at the 19th Annual National Sarasota Congress for Cardiovascular Disease Prevention: Update 2019 jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 1-2, 2019, in Sarasota, FL
8. Novel Drugs for the Treatment of Diabetes, presented at the 19th Annual National Sarasota Congress for Cardiovascular Disease Prevention: Update 2019 jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 1-2, 2019, in Sarasota, FL
9. Diabetic heart Disease, presented at the 19th Annual National Sarasota Congress for Cardiovascular Disease Prevention: Update 2019 jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 1-2, 2019 in Sarasota, FL
10. Putting Guidelines into Practice: New Recommendations for Optimal Treatment of Heart Failure with Reduced Ejection Fraction (T-HFS-1333495), Sponsored by Novartis Pharmaceuticals Corporation February 3, 2017 in Sarasota, FL
11. Appropriate Use Criteria for Cardiovascular Disease Risk Assessment with Emphasis on Cardiovascular Computed Tomography (CCT) presented at the 18th Annual National Sarasota Congress on Cardiovascular Disease Prevention: Update 2018 jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 2-3, 2018 in Sarasota, FL
12. Novel Evidence Based Approach for Early Detection of CVD in Asymptomatic Subjects: New Data From Our Center ) presented at the 18th Annual National Sarasota Congress on Cardiovascular Disease Prevention: Update 2018 jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 2-3, 2018 in Sarasota, FL
13. Current Treatment of Dyslipidemia Beyond Statin: PCSK9 Inhibitor: Update 2018 ) presented at the 18th Annual National Sarasota Congress on Cardiovascular Disease Prevention: Update 2018 jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 2-3, 2018, in Sarasota, FL
14. Cardio Obesity, presented at the 18th Annual National Sarasota Congress on Cardiovascular Disease Prevention: Update 2018 jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 2-3, 2018, in Sarasota, FL
15. Diagnostic and prognostic Value of Coronary Calcium Score ) presented at the 18th Annual National Sarasota Congress on Cardiovascular Disease Prevention: Update 2018 jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVP), The Cardiovascular Health Assessment Center and The Cardiovascular Center of Sarasota Foundation for Research and Education, The Florida Medical Association February 2-3, 2018, in Sarasota, FL
16. Obesity Even without Comorbidities is a Significant Risk Factor with Cardiovascular Disease, presented at Sarasota Memorial Hospital Grand Rounds January 5, 2018, in Sarasota, Florida.
17. Novel Anticoagulant for Stoke Prevention in AF and Deep Vein Thrombosis and PE Treatment, presented at the 13th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Health Assessment Center of Sarasota at The Cardiovascular Center of Sarasota, Sarasota Memorial Healthcare Foundation and Sarasota Memorial Healthcare System, February 3, 2017, in Sarasota, Flor
18. Novel Approach for Cardiovascular Disease Risk Assessment; original Observation from Cardiovascular Center of Sarasota, presented at the 13th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Health Assessment Center of Sarasota at The Cardiovascular Center of Sarasota, Sarasota Memorial Healthcare Foundation and Sarasota Memorial Healthcare System, February 4, 2017, in Sarasota, Florida
19. Obesity is a Disease: Update 2017, Presented at the 13th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Health Assessment Center of Sarasota at The Cardiovascular Center of Sarasota, Sarasota Memorial Healthcare Foundation and Sarasota Memorial Healthcare System, February 4, 2017, in Sarasota, Florida
20. Novel drug for the treatment of heart failure update 2016 3rd annual AKMG convention Miami, FL

July 2016

1. Current treatment for Dyslipidemia beyond Statins, PCSKA Inhibitors, update 2016, 37th annual AKMG convention Miami, FL 2016
2. Know You’re A,B,C and TLC For Healthy Heart Presented at the 11th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Health Assessment Center of Sarasota at The Cardiovascular Center of Sarasota, Sarasota Memorial Healthcare Foundation and Sarasota Memorial Healthcare System, February 7, 2015, in Sarasota, Florida.
3. Optimal Management of Dyslipidemia Beyond Statin: Paradigm Shift to Mono Clonal Antibody: PCSK9 Inhibitor, presented at the 11th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Health Assessment Center of Sarasota at The Cardiovascular Center of Sarasota, Sarasota Memorial Healthcare Foundation and Sarasota Memorial Healthcare System, February 7, 2015, in Sarasota, Florida
4. Obesity is the Risk Factors for Cardiovascular Disease, presented at the 27th Annual 23rd International Cardiovascular Disease Prevention Symposium, Vienna, Budapest and Bucharest June 2 to June 14, 2014 jointly sponsored by the Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation for Education and Research, and Sarasota Memorial Healthcare Foundation in cooperation with the American Society for Preventive Cardiology.
5. Novel Approach for the Current and Future Management of Dyslipidemia Beyond Statin Presented at the 10th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Health Assessment Center at The Cardiovascular Center of Sarasota, Doctors Hospital of Sarasota, Sarasota Memorial Healthcare Foundation and University of Minnesota Center for Cardiovascular Disease Prevention, February 1, 2014, in Sarasota, Florida.
6. Stroke Prevention in Non-valvular Atrial Fibrillation with Novel Anticoagulants: Update 2014 Presented at the 10th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Health Assessment Center at The Cardiovascular Center of Sarasota, Doctors Hospital of Sarasota, Sarasota Memorial Healthcare Foundation and University of Minnesota Center for Cardiovascular Disease Prevention, February 1, 2014, in Sarasota, Florida
7. Prediabetes, Prehypertension and Obesity Even Without Associated Comorbidities Are Risk Factors For Cardiovascular Disease: Time For Early Detection And Implementation Of Individualized Treatment Presented at the 10th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Health Assessment Center at The Cardiovascular Center of Sarasota, Doctors Hospital of Sarasota, Sarasota Memorial Healthcare Foundation and University of Minnesota Center for Cardiovascular Disease Prevention, February 1, 2014 in Sarasota, Florida.
8. Obesity and Perivascular Adiposity as Major Cardiovascular Risk Factors, presented at the 9th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Disease Assessment Center at The Cardiovascular Center of Sarasota, Doctors Hospital of Sarasota, and Sarasota County Medical Society, February 2nd, 2013 in Sarasota, Florida
9. Novel Anticoagulant for Stroke Prevention in Non-Valvular Atrial Fibrillation: Update 2013, Presented at the 9th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Disease Assessment Center at The Cardiovascular Center of Sarasota, Doctors Hospital of Sarasota, and Sarasota County Medical Society, February 2nd, 2013, in Sarasota, Florida.
10. Novel Approach for Optimal Management of Hyperlipidemia beyond Statin with Proprotein Convertase Subtilisin/Kexin 9(PCSK9) Inhibitor Presented at the 9th Annual Cardiovascular Symposium jointly sponsored by Cardiovascular Disease Assessment Center at The Cardiovascular Center of Sarasota, Doctors Hospital of Sarasota, and Sarasota County Medical Society, February 2nd, 2013, in Sarasota, Florida.
11. Oral Presentation “Pre-Hypertension is a Disease Associated with Significant Structural and Functional Cardiovascular Abnormalities. It is Time to Lower the Bar, presented at the American Heart Association High Blood Pressure Research 2012 Scientific Sessions, September 22, 2012, in Washington, DC.
12. Obesity- Is It Harmful for Your Heart? Presented at the 8th Annual Cardiovascular Symposium jointly sponsored by Sarasota Memorial Healthcare Foundation and Cardiovascular Center of Sarasota, February 4th, 2012
13. Novel Approach for Stroke Prevention in Atrial Fibrillation in 2012 Presented at the 8th Annual Cardiovascular Symposium jointly sponsored by Sarasota Memorial Healthcare Foundation and Cardiovascular Center of Sarasota, February 4th, 2012
14. One Ounce of Prevention is Better than One Pound of Cure Presented at the 7th Annual, Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota, Sarasota Memorial Hospital Healthcare Foundation, Sarasota Memorial Hospital and the Cardiovascular Division of the University of South Florida, February 5th, 2011in Sarasota, FL
15. Novel Approaches to Cardiovascular Disease Risk Stratifications Beyond Framingham. Presented at University of South Florida-Health Department of Cardiovascular Diseases on March 10, 2011, in Tampa, Florida.
16. Cardiovascular Disease Risk Assessment beyond Framingham: Update 2011. Presented at the 7th Annual, Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota, Sarasota Memorial Hospital Healthcare Foundation, Sarasota Memorial Hospital and the Cardiovascular Division of the University of South Florida, February 4th, 2011in Sarasota, FL
17. M. El Shahawy, MD, “Calcium Scanning and Scoring. What it all means? Presented at Level 2 Course Certification Sponsored by the University of Arizona, held at the Institute for Advanced Medicine in Sarasota Florida, May 21-23, 2010
18. CARDIAC CTA: Answers to Questions You Might Have Been Afraid to Ask About Radiation, Presented at Level 2 Course Certification Sponsored by The University of Arizona, held at the Institute for Advanced Medicine in Sarasota Florida, May 21-23, 2010
19. SMH, Cardiovascular Disease Assessment Center. What have we accomplished? Presented at the 6th Annual, Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota, Sarasota Memorial Hospital Healthcare Foundation, Sarasota Memorial Hospital of Sarasota and the Cardiovascular Division of the University of South Florida, February 6th, 2010, in Sarasota, FL
20. The Cardio Metabolic Syndrome as major killer: Update 2010. Presented at the 6th Annual, Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota, Sarasota Memorial Hospital health care Foundation, Sarasota Memorial Hospital of Sarasota and the Cardiovascular Division of the University of South Florida, February 6th, 2010, in Sarasota, FL
21. The Metabolic Syndrome as a major Killer, presented at the 5th Annual, Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota, Sarasota Memorial Hospital Healthcare Foundation, Sarasota Memorial Hospital and the Cardiovascular Division of the University of South Florida, February 7th, 2009in Sarasota, FL
22. Cardiovascular Disease Prevention Center, When? Where? and What? Presented at the 4th Annual, Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota, Sarasota Memorial Hospital health care Foundation, Sarasota Memorial Hospital of Sarasota and the Cardiovascular Division of the University of South Florida, February 9th, 2008in Sarasota, FL
23. Peripheral Arterial Disease as Major Clue for Cardiovascular Disease. Presented at the 3rd Annual, Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota, Sarasota memorial hospital health care Foundation, Sarasota Memorial Hospital of Sarasota and the Cardiovascular Division of the University of South Florida. March 2007in Sarasota, FL
24. Cardiovascular Continuum Update 2007 Presented at the 3rd Annual, Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota, Sarasota Memorial Hospital Healthcare Foundation, Sarasota Memorial Hospital of Sarasota and the Cardiovascular Division of the University of South Florida. March 2007in Sarasota, FL
25. What is Metabolic Syndrome? How Does One Diagnose This? Local or Global? - Panel Meeting – Tuesday, March 9, 2004 at the 53rd Annual Scientific Session American College of Cardiology, March 7 – March 10, 2004, New Orleans, Louisiana.
26. Chronic Stable Angina Pectoris: Current Diagnosis and Management- Panel Meeting – Sunday March 30, 2003, at the 52nd Annual Scientific Session American College of Cardiology, March 30 – April 2, 2003, Chicago, Illinois.
27. Aggressive Management of Cardiovascular Risk Factors, presented at the Florida Academy of Family Physicians Annual Meeting, Sponsored by Foundation for Better Health Care, April 19, 2002, Ft. Lauderdale, Florida.
28. Atrial Fibrillation and Stroke Prevention In Diabetic Patients, presented at the 31st Annual Scientific Symposium Hungarian Medical Association of America October 24 – 29, 1999, Sarasota, Florida.
29. Updates on Calcium Channel Blockers for the Treatment of Hypertension and Angina Pectoris. Presented to Pinehurst Medical Group. Pinehurst, North Carolina. September 16, 1997. Pinehurst Country Club and Resorts.
30. Atrial Fibrillation: New Standard of Care presented at the 28th Annual Scientific Symposium of the Hungarian Medical Association of America, Inc., October 27-November 1, 1996. Sarasota, FL
31. Cardiovascular Complications of Diabetes Mellitus presented at the Annual Meeting of Diabetic: Nurses, May 15-19, 1996, in Longboat Key, FL.
32. Hypertrophic Cardiomyopathy-Newer Treatment Modalities presented at the 27th Annual Scientific Symposium of the Hungarian Medical Association of America, October 22-27, 1995, in Sarasota, FL.
33. M. El Shahawy, M.D., “Echocardiography in the Diagnosis of Valvular Heart Disease”, presented at the Non-Invasive Cardiovascular Evaluation 1974, January 25, 1974. University of Florida. Gainesville, Florida.
34. Demonstration of Echocardiographic Exam presented at the Non-Invasive Cardiovascular Evaluation. January 24, 1974. University of Florida. Gainesville, Florida.
35. Basic Principals of Echocardiography and Instrumentation presented at the Non-Invasive Cardiovascular Evaluation. January 24, 1974. University of Florida. Gainesville, Florida.
36. Thyroid Hormones and the Prevention of Heart Block presented at the First Annual Research Symposium of the Florida Heart Association on January 19, 1974, Tampa, Florida
37. Non-Invasive Study of the Effect of Isometric Exercise on the Size and Performance of the Normal Heart presented at the American Heart Association 46th Scientific Sessions, November 1973, Atlantic City, New Jersey.
38. The Effect of Thyroid Hormone and B-Blockade on Renin Release in Hyperthyroid Dogs presented at the American Heart Association 45th Scientific Sessions, November 16-19, 1972, in Dallas, Texas.
39. The Effect of Thyroid Hormone on Intracardiac Conduction with and without Propranolol presented at the American Heart Association 45th Scientific Sessions, November 16-19, 1972, in Dallas, Texas.
40. Increased Plasma Renin Activity and Secondary Aldosteronism in Hyperthyroidism: Augmentation by Magnesium Deficiency presented at the Annual Meeting of the AHA in Anaheim, California on

November 16, 1971.

1. Cardiovascular Effects of Magnesium Deficiency and Thyroxin Administration Presented at the Annual Meeting of A.C.C.P. October 26, 1971.
2. M. El Shahawy, et. al; “Selected Observations on Hyperthyroid, Magnesium-Deficient Dogs”, presented at the Research Club, Mayo Clinic, Rochester, MN, Mayo Clinic Bulletin, April 23, 1971.
3. M. El Shahawy, M.D.; “The Effect of Magnesium Deficiency on the Cardiovascular System”, seminar presented at the Physiology Department, Mayo Clinic, Rochester, MN., Mayo Clinic Bulletin., February 12, 1971, No. 7, Vol. 49.

**Invited Speaker/Faculty at International Medical Meetings:**

1. Chairperson; the European Society of Cardiology Congress sessions: “Risk Factors: Obesity” and “Diabetes and the Heart,” held in Amsterdam from 25 to 28 August 2023.
2. Obesity Even Without Comorbidity is a Major Cardiovascular Risk Factor. Presented at 30th Annual International Congress on Cardiovascular Disease Prevention, Update 2022 From Intervention to Prevention “One Ounce of Early Cardiovascular Disease Prevention is Better than Pounds of Late Treatment,” held October 15-October 25, 2022 Cairo, Aswan and Luxor Egypt
3. Excess Epicardial Fat Volume: Novel Cardiovascular Risk Factor.Presented at 30th Annual International Congress on Cardiovascular Disease Prevention, Update 2022 From Intervention to Prevention “One Ounce of Early Cardiovascular Disease Prevention is Better than Pounds of Late Treatment,” held October 15-October 25, 2022 Cairo, Aswan and Luxor Egypt
4. Inform Public Policy: Effectiveness of health promotion in Promoting Cardiovascular Health. Presented as Chairman at 77th Brazilian Congress of Cardiology/ World Congress of Cardiology October 10-13, 2022, Rio de Janeiro, RJ.
5. Excess Epicardial Fat Volume as a Novel Risk Factor for Cardiovascular Complications Including Arrhythmia/Atrial Fibrillation. Novel Data From Our Center in Sarasota, Florida. Presented at DoloMeeting Arrhythmias March 10-11, 2022, Bolzano, Italy
6. My Strategy for Primary and Secondary CVD Prevention in DM; Presented at the 49th International Congress of the Egyptian Society of Cardiology, CardioEgypt February 21-24, 2022 in New Cairo, Egypt.
7. Epicardial Fat, a Part of Visceral Obesity or a Specific Risk Factor; Presented at the 49th International Congress of the Egyptian Society of Cardiology, CardioEgypt February 21-24, 2022 in New Cairo, Egypt.
8. Obesity Is A Risk Marker for Cardiovascular Disease: Emphasis on Cardio Obesity; CardioEgypt 2021 December 17-18, 2021 in Cairo, Egypt.
9. Women’s Heart Disease. Presented at Women’s Heart Day on November 5, 2021 in Cairo, Egypt.
10. Obesity is a Disease With and Without Co-morbidities: With an Emphasis on Cardio Obesity; New Data and Publications From Our Cardiovascular Center in Sarasota. Presented at the 1st Cardio Prevention Day on October 31, 2021 in El Mahala Kobra, Egypt
11. Early Cardiovascular Disease Detection and/or Prevention is Better than Pounds of Late Cure; Healthy Hearts Association, Shareyah Society on October 30, 2021 in Baltim, Egypt
12. Insight for Cardiovascular Disease Prevention; National Heart Institute Academy on October 9, 2021 in Cairo, Egypt.
13. Diabetic Heart Disease: Update 2021. Presented at the 29th International Congress of the ISCVDP on September 26, 2021 at Split, Croatia.
14. Cardio Renal Syndrome. Presented at the 29th International Congress of the ISCVDP on September 26 at Split, Croatia.
15. Update on Cardiometabolic Risk. Presented at the 29th International Congress of the ISCVDP. on September 25, 2021 in Venice, Italy.
16. Scoring Systems Accurately Estimate CVD Risk in Primary Prevention and should be Applied to All. CardioEgypt 2021 February 15th-18th, 2021 in Cairo, Egypt.
17. My strategy of management in Diabetics in primary and secondary CVD prevention. CardioEgypt 2021 February 15th-18th, 2021 in Cairo, Egypt.
18. Epicardial fat, a part of visceral obesity or a specific risk factor. CardioEgypt 2021 February 15th-18th, 2021 in Cairo, Egypt.
19. Chairperson; Joint session with WHF. CardioEgypt 2021 February 15th-18th, 2021 in Cairo, Egypt.
20. Chairperson; Joint session with ISCVDP. CardioEgypt 2021 February 15th-18th, 2021 in Cairo, Egypt.
21. Speaker at the 22ndt Annual Meeting of Preventive Cardiology and Rehabilitation Working Group “CardioPrevent” October 13, 2020 in Cairo, Egypt
22. Can We Reduce Microvascular Complications in Diabetes, presented at 11th Annual Arab Diabetes Forum October 8th-9th, 2020 held virtually.
23. Hypertriglyceridemia in Asymptomatic Subjects is an Early Indicator of structural and Functional Abnormalities, presented at 47th Annual International Congress of the Egyptian Society of Cardiology February 24, 2020 in Cairo, Egypt.
24. Calcium Scoring and Cardiac Adipose Tissue: Novel Imaging Markers for Risk Stratification, presented at 47th Annual International Congress of the Egyptian Society of Cardiology February 25, 2020 in Cairo, Egypt.
25. Dyslipidemia Beyond Statin/Ezetimibe and PCSK9 Inhibitors with Focus on Hypertriglyceridemia, presented at Luxor Cardiology January 9, 2020 in Cairo, Egypt
26. Drug Treatment Menu, Expected Newcomers with Early Signaling of Benefit: Focus on Novel Concepts on Lipid and Glucose lowering RX What every cardiologist should know – presented at 21st Annual Meeting of Preventive Cardiology and Rehabilitation Working Group “CardioPrevent” November 6, 2019 in Cairo, Egypt
27. The Importance of a Healthy Diet in Cardiovascular Health with Emphasis on Purified Fish Oil, presented at Annual Congress Internationally for Disease Prevention and Treatment in Fish at the Egyptian National Center for Research November 4, 2019 in Cairo, Egypt.
28. Lipid Lowering Beyond Statins and PCSK9 Inhibitors, presented at 6th Cardiology Conference of Suez Canal Authority (ACSCA) November 1, 2019 in Ismailia, Egypt.
29. Epicardial Adiposity as novel Cardiovascular Risk Factor, presented at 28th International Congress on Cardiovascular Disease Prevention in Malaga, Spain July 19, 2019
30. Diabetic Heart Disease, presented at 28th International Congress on Cardiovascular Disease Prevention in Lisbon, Portugal July 15, 2019
31. Current Guidelines for Detection, Prevention and Treatment of Hypertension, presented at 28th International Congress on Cardiovascular Disease Prevention in Lisbon, Portugal July 14, 2019
32. New Guidelines for the Treatment of Hypertension, presented at X International Conference on Arterial Hypertension and Cardiovascular Disease Prevention, Vitebsk, Belarus May 30-31, 2019
33. Preventive Cardiology: State of the Art, presented at the 6th Annual Meeting of Cardiology & Angiology Unit of Medical Research Institute, Alexandria University, Alexandria, Egypt, April 18, 2019
34. Novel Approach for Cardiovascular Disease Risk Assessment, presented at the Preventive Cardiology Working Group of the Egyptian Society of Cardiology in Collaboration with the National Training Institute, Cairo, Egypt April 17, 2019
35. Epicardial Fat What That Means for the Clinical Cardiologists and How to Measure, presented at the   
    46th Annual Congress Cairo, Egypt February 24-28, 2019
36. How to Avoid Sudden Cardiac Death in Athletes. presented at the Ministry of Youth and Sports, Cairo, Egypt, February 16, 2019
37. Obesity is a Disease Even Without Comorbidities, presented at World Congress of Cardiology and Cardiovascular Health 2018, Dubai, United Arab Emirates, December 6, 2018
38. PCSK9-I: Lessons derived from clinical trial, presented at the CardioRisk-EAVA Hurghada, Egypt, November 21-24, 2018
39. Novel Approach for Early Cardiovascular Health Assessment in Asymptomatic Subjects: Novel Data from our Center, presented at 20th Annual Meeting of Preventive Cardiology & Rehabilitation Working Group of the Egyptian Society of Cardiology, Cairo, Egypt, November 15-16, 2018
40. Preventive Cardiology, The Past, Present and Future, presented at 20th Annual Meeting of Preventive Cardiology & Rehabilitation Working Group of the Egyptian Society of Cardiology, Cairo, Egypt, November 15-16, 2018
41. Current Treatment of Dyslipidemia Beyond Statin: PCSK9 Inhibitors Update 2018 Presented at 27th International Congress on Cardiovascular Disease Prevention, Paris and Normandy Countryside, France July 22-29, 2018
42. Diabetic Heart Disease, Presented at 27th International Congress on Cardiovascular Disease Prevention, Paris and Normandy Countryside, France July 22-29, 2018
43. Obesity Even Without Comorbidities is a Disease, Presented at 27th International Congress on Cardiovascular Disease Prevention, Paris and Normandy Countryside, France July 22-29, 2018
44. Cardio-Metabolic Syndrome (Latest American Guidelines- 2018) at the Sparaco Metabolic Syndrome Forum, Dubai, UAE April 27, 2018
45. Diabetic Heart Diseases, Why Different? at the Sparaco Metabolic Syndrome Forum, Dubai, UAE April 27, 2018
46. Obesity Even Without Comorbidities is a Disease- New Data from our CVS Center at the Sparaco Metabolic Syndrome Forum, Dubai, UAE April 27, 2018
47. Epicardial Fat is Novel Cardiovascular Risk Factor, El Mehala El Cobra April 25, 2018
48. Excess Epicardial Fast as a Novel Risk Factor Beyond Abdominal Visceral Adiposity, Europrevent 2018 Congress, Ljubljana, Slovenia April 19-21, 2018
49. Novel Modality and Approach for Cardiovascular Disease Risk Assessment: Update 2018, 45th Annual International Congress of the Egyptian Society of Cardiology “CardioEgypt 2018” February 27, 2018
50. Obesity is a Disease Even Without Comorbidities: Update on Novel Data 2018, 45th Annual International Congress of the Egyptian Society of Cardiology “CardioEgypt 2018” February 27, 2018
51. Excess Epicardial Fat is a Major Risk Marker for Cardiovascular Disease: Novel Data from our Center, 45th Annual International Congress of the Egyptian Society of Cardiology “CardioEgypt 2018” March 1, 2018
52. SIHD General Medicine Practices for Healthcare Providers at the Bangladesh Medical Association of North America Annual Scientific Seminar, Orlando, FL July 27th-30th, 2017
53. NOAC for Stoke Prevention in NVAF & DVT/PE Prevention and Treatment at the 30th Annual 26th International Congress Fowey, Cornwall, UK-London/Portsmouth , June 10, 2017
54. Current Treatment of Dyslipidemia beyond Statin: PCSK9 Inhibition: Update 2017 at the 30th Annual 26th International Congress Dublin, Ireland, June 6, 2017
55. Obesity is a Disease Even Without Comorbidities: New Data from Our Center at the 30th Annual 26th International Congress Portree Isle of Sky UK, June 4, 2017
56. Novel Evidence Based Approach for Early Detection of CVD in Asymptomatic Subjects: New Data from Our Center at the 30th Annual 26th International Congress Reykjavik, Iceland June 1, 2017
57. Perivascular Adiposity is not just a Scaffold, at the 44th Annual International Congress of the Egyptian Society of Cardiology, Cairo, Egypt February 22, 2017.
58. Pharmacotherapy Options for Obesity and Cardiometabolic Risk: Helpful or Harmful? at the 44th Annual International Congress of the Egyptian Society of Cardiology, Cairo, Egypt February 22, 2017.
59. Juvenile Obesity, an emerging problem. at the 44th Annual International Congress of the Egyptian Society of Cardiology, Cairo, Egypt. February 20, 2017.
60. Novel Approach for Cardiovascular Disease Risk Assessment presented First Annual

Symposium of the University of Zagazig Medical School, February 19, 2017.

1. Novel drugs for the treatment of heart failure at the Slovenian Society of Cardiology annual meeting in Ljubljana, Slovenia June 2016
2. Current recommendations of the use of NOACS annual meeting in Ljubljana, Slovenia, June 2016
3. Heart Failure: New Treatments Presented at the 29th Annual 25th International Cardiovascular Disease Prevention Symposium, Dubrovnik, Croatia June 10, 2016
4. Current Treatment of Dyslipidemia Beyond Statin: PCSK9 Inhibitors Update 2016 Presented at the 29th Annual 25th International Cardiovascular Disease Prevention Symposium, Split, Croatia June 09, 2016
5. Novel Evidence Based Approach for Early Detection of CVD Presented at the 29th Annual 25th International Cardiovascular Disease Prevention Symposium, Venice, Italy June 07, 2016
6. Novel Tools and Risk Score for Early Detection of Cardiovascular Disease: 4th Dubrovnic Cardiology Highlights, An ESC Update Program in Cardiology, DUBROVNIK, CROATIA, October 10-13, 2015
7. Stroke and Deep Vein Thrombosis Prevention: Update 2015 Presented at the 28th Annual 24th International Cardiovascular Disease Prevention Symposium, LIMA, PERU July 15, 2015
8. Monoclonal Antibody for the Management of Dyslipidemia: PCSK9 Inhibitor Presented at the 28th Annual 24th International Cardiovascular Disease Prevention Symposium, LIMA, PERU, July 14, 2015
9. Obesity Even Without Comorbidities Is A Disease: Here Is the Evidence? Presented at the 28th Annual 24th International Cardiovascular Disease Prevention Symposium, Quito, Ecuador, July 13, 2015
10. Novel Approach for Early Cardiovascular Health Assessment: Individualized Model for Community-wide Screening Presented at the 28th Annual 24th International Cardiovascular Disease Prevention Symposium, Quito, Ecuador, July12, 2015
11. Novel Tools for Early Cardiovascular Disease Risk Assessment, The 23rd Annual Meeting of the Alpe Adria Association of Cardiology 3-6 June 2015 in Bled, Slovenia.
12. Update on Novel Oral Anticoagulants 2015, The 23rd Annual Meeting of the Alpe Adria Association of Cardiology 3-6 June 2015 in Bled, Slovenia.
13. M. El Shahawy, MD, “Management of dyslipidemia beyond statins” Presented at the 42nd Annual International Congress of The Egyptian Society of Cardiology, February 24th, 2015 in Cairo, Egypt.
14. M. El Shahawy, MD, “Obesity is a disease even without Comorbidities” Presented at the 42nd Annual International Congress of The Egyptian Society of Cardiology, February 24th, 2015 in Cairo, Egypt.
15. M. El Shahawy, MD, “Monoclonal antibodies: Paradigm shift in lipid management” presented at Cardio Lipid 2014 November 13, 2014 in Hurghada, Egypt.
16. M. El Shahawy, MD,: “Novel Anticoagulant for Stroke Prevention in Atrial Fibrillation: Part 1” Presented at the 27th Annual 23rd International Cardiovascular Disease Prevention Symposium, Vienna, Budapest and Bucharest June 2 to June 14, 2014 jointly sponsored by the Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation for Education and Research, and Sarasota Memorial Healthcare Foundation in cooperation with the American Society for Preventive Cardiology.
17. M. El Shahawy, MD,: “Novel Approach for the Management of Dyslipidemia beyond Statin: PCSK9 Inhibitor” Presented at the 27th Annual 23rd International Cardiovascular Disease Prevention Symposium, Vienna, Budapest and Bucharest June 2 to June 14, 2014 jointly sponsored by the Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation for Education and Research, and Sarasota Memorial Healthcare Foundation in cooperation with the American Society for Preventive Cardiology.
18. M. El Shahawy, MD, “Novel Anticoagulant for Stroke Prevention in Non-Valvular Atrial Fibrillation: Update 2013”, Presented at the 26th Annual, 22nd International Cardiovascular Symposium, Sweden, Russia, Poland, and Germany June 25 to July 5, 2013, jointly sponsored by the Cardiovascular Disease Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation for Education And Research, and Sarasota Memorial Healthcare Foundation.
19. M. El Shahawy, MD, “Novel Approach for Optimal Management of Hyperlipidemia beyond Statin with Proprotein Convertase Subtilisin/Kexin 9, Presented at the 26th Annual, 22nd International Cardiovascular Symposium, Sweden, Russia, Poland, and Germany June 25 to July 5, 2013, jointly sponsored by the Cardiovascular Disease Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation For Education And Research, and Sarasota Memorial Healthcare Foundation
20. M. El Shahawy, MD, “Epicardial Adiposity as a Novel Risk Factor: Diagnosis and Management”, Presented at the 26th Annual, 22nd International Cardiovascular Symposium, Sweden, Russia, Poland, and Germany June 25 to July 5, 2013, jointly sponsored by the Cardiovascular Disease Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation For Education And Research, and Sarasota Memorial Healthcare Foundation.
21. M. El Shahawy, MD, “Novel Anticoagulant for Stroke Prevention in Non-Valvular Atrial Fibrillation: Update 2012”, Presented at the 9th Congress of the Croatian Cardiac Society, October 13th - 16th, 2012, Opatia, Croatia.
22. M. El Shahawy, MD, “Risk Factor: It Is More Than a Scaffold”, presented at the 9th Congress of the Croatian Cardiac Society, October 13th - 16th, 2012, Opatia, Croatia.
23. M. El Shahawy, MD, “Novel Anticoagulant for Stroke Prevention in Atrial Fibrillation”, Presented at the 25th Annual, 21st International Cardiovascular Symposium, England and Norway, June 22 to July 6, 2012, jointly sponsored by the Cardiovascular Disease Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation For Education And Research, and Sarasota Memorial Healthcare Foundation.
24. M. El Shahawy, MD, “ The Cardio metabolic Syndrome”, Presented at the 25th Annual, 21st International Cardiovascular Symposium, England and Norway, June 22 to July 6, 2012, jointly sponsored by the Cardiovascular Disease Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation for Education and Research, and Sarasota Memorial Healthcare Foundation
25. M. El Shahawy, MD, “Novel Approach for Cardiovascular Disease Risk Assessment: beyond Framingham” presented at the Slovenian Society of Cardiology 20th Annual Meeting, May 12, 2012, Radenci, Slovenia.
26. M. El Shahawy, MD, “Perivascular Adipose Tissue: More Than a Scaffold”, presented at the World Congress of Cardiology, April 18th - 21st, 2012, Dubai, United Arab Emirates.
27. M. El Shahawy, MD, “Obesity is a disease even in Asymptomatic normotensive subjects: what is the evidence and why?”, presented at the 15th Meeting of the Egyptian Hypertension Society, April 11-12, 2012, Cairo, Egypt.
28. M. El Shahawy, MD, “Carotid Intima Media Thickness (CIMT) Measurement for Cardiovascular Disease Risk Stratification in Newly Diagnosed Asymptomatic Hypertensive Subjects”, presented at the 39th Annual Congress of The Egyptian Society of Cardiology, February 28th, 2012, Cairo, Egypt.
29. M. El Shahawy, MD, “Stroke Prevention in Atrial Fibrillation: Update 2011”, presented at the 38th Annual Congress of The Egyptian Society of Cardiology, October 18th -22nd, 2011, Sharm El-Sheikh – Egypt.
30. M. El Shahawy, MD, “Novel approach for cardiovascular Disease risk Assessment in 2011”, presented at the 38th Annual Congress of The Egyptian Society of Cardiology, October 18th -22nd, 2011, Sharm El-Sheikh – Egypt.
31. M. El Shahawy, MD, “Cardiac CT update 2011” Presented at the 24th Annual, 20th International Cardiovascular Symposium, in Cape Town, South Africa, July 21st to 28th, 2011 jointly sponsored by the Cardiovascular Institute of Sarasota, Sarasota Memorial Hospital Healthcare Foundation, Sarasota Memorial Hospital and the Cardiovascular Division of the University of South Florida.
32. M. El Shahawy, MD, “Global Cardiovascular Risk Factors: Update 2011” Presented at the 24th Annual, 20th International Cardiovascular Symposium, in Cape Town, South Africa, July 21st - 28th, 2011 jointly sponsored by the Cardiovascular Institute of Sarasota, Sarasota Memorial Hospital Healthcare Foundation, Sarasota Memorial Hospital and the Cardiovascular Division of the University of South Florida
33. M. El Shahawy, MD, “Time to Mandate a More Accurate tool to Assess CVD risk in Women beyond Framingham” presented at the 37th Annual Congress of The Egyptian Society of Cardiology, February 23 - 25, 2010, Cairo, Egypt
34. M. El Shahawy, MD, “Rise in Systolic Blood Pressure Over 30mmHg After Mild Exercise As A New Marker For Early Cardiovascular Disease Risk Stratification in Asymptomatic Normotensive Patients Regardless of sex presented at the 37th Annual Congress of The Egyptian Society of Cardiology, February 23rd to 25th, 2010, Cairo, Egypt.
35. M. El Shahawy, MD, “New Cardiovascular Disease Risk Scoring System Beyond Framingham” presented at the 37th Annual Congress of The Egyptian Society of Cardiology, February 23 to 25, 2010, Cairo, Egypt
36. M. El Shahawy, MD, “Cardiac CT: Answers to questions you might have been afraid to ask”. Presented at the 22nd Annual, 18th International Cardiovascular Symposium, in Switzerland and Germany, September 4th to 14th 2009 sponsored by CVIS and The University of South Florida.
37. M. El Shahawy, MD, “The Value of Coronary Calcium Scoring by CCT In The Diagnosis and Prevention of Coronary Artery Disease” Presented at the 22nd Annual, 18th International Cardiovascular Symposium, in Switzerland and Germany, September 4th to 14th 2009 sponsored by CVIS And The University of South Florida.
38. M. El Shahawy, MD, “Cardio Metabolic Syndrome: Update ’08” , Presented at the 21st Annual, 17th International Cardiovascular Symposium, in Romania and Turkey, sponsored by CVIS and the University of South Florida August 24 – 28, 2008.
39. M. El Shahawy, M.D., “Cardiovascular Risk Factors Assessment: Overview 2008”, Presented at the 21st Annual, 17th International Cardiovascular Symposium, in Romania and Turkey, sponsored by CVIS and The University of South Florida, August 24 - 28, 2008.
40. M. El Shahawy, M.D., “Obesity and Thrombosis” presented at the 35th Annual Congress of The Egyptian Society of Cardiology, February 25th – 29th, 2008, Cairo, Egypt.
41. M. El Shahawy, M.D., “Immune Modulation of Atherosclerosis” presented at the 35th Annual Congress of The Egyptian Society of Cardiology, February 25th – 29th, 2008, Cairo, Egypt.
42. M. El Shahawy, M.D., A Peripheral Arterial Disease as a Clue to Cardiovascular and Cerebrovascular Disease”, Presented at the 20th Annual, 16th International Cardiovascular Symposium, in India’s Golden Triangle October 22nd November 2nd, 2007.
43. M. El Shahawy, M.D., Pulseless VT/VF Presented at AHA sponsored International Symposium on BLS/ACLS/ Instructor Course in New Delhi, India at Max Health Care Institution, October 18-26th 2007.
44. M. El Shahawy, M.D., Tachycardia, Stable and Unstable. Presented at AHA sponsored international Symposium on BLS/ACLS/ Instructor Course in New Delhi, India at Max Health Care Institution from October 18-26th 2007.
45. M. El Shahawy, M.D, STROKE. Presented at AHA sponsored International Symposium on BLS/ACLS/ Instructor Course in New Delhi, India at Max Health Care Institution from October 18 26th 2007.
46. M. El Shahawy, M.D.: Acute Coronary Syndrome. Presented at AHA sponsored international Symposium on BLS/ACLS/ Instructor Course in New Delhi, India at Max Health Care Institution from October 18-26th 2007.
47. M. El Shahawy, M.D., “The Cardio Metabolic Syndrome: Current Diagnosis and Management 2006”, Presented at the 19th Annual, 15th International Cardiovascular Symposium, October 13-25, 2006, ITALY, EGYPT GREECE, and Turkey.
48. M. El Shahawy, M.D., “Metabolic Syndrome Current Diagnosis and Management”, Presented at the 18th Annual, 14th International Cardiovascular Symposium, Nov 29th to Dec. 12th, 2005, Republic of Seychelles, Madagascar, Mauritius and Cape Town (South Africa).
49. M. El Shahawy, M.D, “Dysmetabolic Syndrome” Presented at the 17th Annual, 13th International Cardiovascular Symposium, July 17th –July 29th, 2004, Austria, Slovenia and Italy.
50. M. El Shahawy, M.D, “Peripheral Arterial Disease in Diabetic: Current Diagnosis and Management” Presented at the 16th Annual, 12th International Cardiovascular Symposium, October 24th –November 7, 2003, Spain and Portugal.
51. M. El Shahawy, M.D., “The Dysmetabolic Cardiac Syndrome” presented at the 16th annual, 12th International Cardiovascular Symposium, October 24th –November 7, 2003, Spain and Portugal.
52. M. El Shahawy, M.D.;” Dysmetabolic Cardiac Syndrome” presented at the 4th Annual New Year Symposium of the Association of American Black Cardiologists “ABC”, Western Caribbean, and December 28, 2002- January 4, 2003.
53. M. El Shahawy, M.D., “Cardiovascular Risk Reduction in High Risk Patients with A.C.E.I.: Emphasis on Diabetics with the “H.O.P.E. and Micro H.O.P.E. to Redefine Therapy. Part II presented at the 15th Annual 11th International Cardiovascular Symposium, August 1st-15th, 2002, British Isles.
54. M. El Shahawy, M.D., “Cardiovascular Risk Reduction in High Risk Patients with A.C.E.I.: Emphasis on Diabetics with the “H.O.P.E. and Micro H.O.P.E. to Redefine Therapy. Part I presented at the 15th Annual 11th International Cardiovascular Symposium, August 1st-15th, 2002, British Isles
55. M. El Shahawy, M.D., “Diabetes and Cardiovascular Disease”, presented at the Family Physicians Academy of Puerto Rico, March 23, 2002- San Juan, Puerto Rico.
56. M. El Shahawy, M.D., “New Treatment of High Risk Cardiovascular Patients, Hope and Micro Hope Trials”, presented at the Nephrology and Hypertension Society of Puerto Rico Annual Meeting, February 23, 2002. San Juan, Puerto Rico.
57. M. El Shahawy, M.D., “Current Treatment of Acute Heart Failure”, presented at the 29th International Conference of the Egyptian Society of Cardiology, February 4-8, 2002. Alexandria, Egypt.
58. M. El Shahawy, M.D., “Diabetic Heart Disease: Current Medical Management”, presented at the 14th Annual 10th International Cardiovascular Symposium, October 16th – 28th, 2001. Caribbean Island
59. M. El Shahawy, M.D,; "Diabetic Heart Disease Update 2001" presented at the 50th Golden Jubilee Congress of the Egyptian Society of Cardiology, February 19-23, 2001.
60. M. El Shahawy, M.D., "Atrial Fibrillation: Have the Mega Trials Answered All the Questions" presented at the 50th Golden Jubilee Congress of the Egyptian Society of Cardiology, February 19-23, 2001.
61. M. El Shahawy, M.D., “Stroke Prevention in Atrial Fibrillation: What Have We Learned from the Mega trials”, presented at the 13th Annual 9th International Cardiovascular Symposium, October 12th – 28th, 2000, Australia and New Zealand.
62. M. El Shahawy, et. al.; “The Latest Information in the Diagnosis and Management of Hypertension” presented at the 13th Annual 9th International Cardiovascular Symposium, October 12th – 28th, 2000, Australia and New Zealand.
63. M. El Shahawy, M.D.; “Heart Failure Update: Current and Future Management”, presented at the 13th Annual 9th International Cardiovascular Symposium, October 12th – 28th, 2000, Australia and New Zealand.
64. M. El Shahawy, M.D.; “Stroke Prevention in Atrial Fibrillation” presented at the 27th Annual Congress of The Egyptian Society of Cardiology, February 21st – 25th, 2000, Cairo, Egypt.
65. M. El Shahawy, M.D., Lecture Of The Year: “Hypertension Update JNC (VI) Current Management” presented at the 27th Annual Congress of The Egyptian Society of Cardiology, February 21st – 25th, 2000, Cairo, Egypt.
66. M. El Shahawy, M.D., “Diabetic Heart Disease Update 2000” presented at the 27th Annual Congress of The Egyptian Society of Cardiology, February 21st – 25th, 2000, Cairo, Egypt.
67. M. El Shahawy, M.D.; “Hypertension Update JNC VI” presented at The 12th Annual 8th International Cardiovascular Symposium in South America from Santiago, Chile to Buenos Aires, Argentina, November 19 – December 7, 1999.
68. M. El Shahawy, M.D., “Diabetic Heart Disease Update 1999” presented at The 12th Annual 8th International Cardiovascular Symposium in South America from Santiago, Chile to Buenos Aires, Argentina, November 19 - December 7, 1999.
69. M. El Shahawy, M.D..; “A, B, C, D, Treatment of Heart Failure” presented at the 26th Annual Meeting of the Egyptian Society of Cardiology in Cairo-Egypt, February 14 - 19, 1999.
70. M. El Shahawy, M.D., "Recent Advances & Strategies for Hypertension Control" presented at the 11th Annual, 7th International Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, on October 17, 1998 in China.
71. M. El Shahawy, M.D., "Diabetic Heart Disease, Update 1998" presented at the 11th Annual, 7th International Cardiovascular Symposium on October 12, 1998 in China.
72. M. El Shahawy, M.D., ''Update on Calcium Channel Blockers for the Treatment of Hypertension and Angina Pectoris" presented at the International Symposium co Heart Disease, "From Molecules to Patient Care", sponsored by the International Society and Federation of Cardiology and the International Academy of Cardiovascular Sciences, May 19-21, 1998 in Cairo, Egypt.
73. M. El Shahawy, M.D., "Heart Failure Current and Future Treatment" presented at the 25th Anniversary Egyptian Society of Cardiology on February 22-27, 1998 in Cairo, Egypt.
74. M. El Shahawy, M.D., "Atrial Fibrillation: Multicenter Trials-Have the Mega trials answered all the Questions? “Presented at the 25th Anniversary Egyptian Society of Cardiology, February 22-27, 1998 in Cairo, Egypt
75. M. El Shahawy, M.D., "Diabetic Cardiomyopathy" presented at the 10th Annual, 6th International Cardiovascular Symposium sponsored by the Cardiovascular Institute of Sarasota Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in Paris, France and Cape Town, South Africa, November 21-December 4, 1997.
76. M. El Shahawy, M.D., "Selective T-Channel Blockade for the Treatment of Hypertension and Angina Pectoris in 1997 (A New Cardiovascular Era)" Presented at the 10th Annual, International Cardiovascular Symposium sponsored by the Cardiovascular Institute of Sarasota Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in Paris, France and Cape Town, South Africa, November 2 l-December 4, 1997.
77. M. El Shahawy, M.D., "Cardio-embolic Stroke" presented at the Egyptian Society of Cardiology 24th Annual Meeting. Cairo, Egypt. February 24-28, 1997.
78. M. El Shahawy, M.D., "Atrial Fibrillation: Review of Multi-Center Anticoagulation Studies" presented at the 1st International Symposium on Cardiac Arrhythmia on February 23, 1997. Cairo, Egypt. Jointly sponsored by the Egyptian Society of Cardiology and the North American Society of Pacing and Electrophysiology (NASPE).
79. M. El Shahawy, M.D., "Cardio embolic Stroke Prevention" presented at the 9th Annual, 5th International Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in London, England, Scandinavia, and St. Petersburg, Russia, August 20-September 4, 1996.
80. M. El Shahawy, M.D., "Prevention of Stroke in Atrial Fibrillation" presented at the XXIII Congress of the Egyptian Society of Cardiology, February 28-March 2, 1996 in Luxor, Egypt
81. M. El Shahawy, M.D., "Recent Advances in the Treatment of Hypertrophic Cardiomyopathy” “I.H.S.S”, presented at the 8th Annual, 4th International Cardiovascular Symposium, jointly sponsored by the Cardiovascular Institute of Sarasota and the University of Florida, held in Rome, Italy and Barcelona, Spain, September 26-October 9, 1995.
82. M. El Shahawy, M.D., "Cardiomyopathies-Newer Insights" presented at the 7th Annual, 3rd International Cardiovascular Symposium, jointly sponsored by the University of Florida, University of Vienna (Austria) and the Cardiovascular Institute of Sarasota, held in Vienna, Austria, September 15-27, 1994
83. M. El Shahawy, M.D., "Mitral Valve Prolapse-What is New?' presented at the 7th Annual, 3rd International Cardiovascular Symposium, jointly sponsored by the University of Florida and the Cardiovascular Institute of Sarasota, held in Athens, Greece and Istanbul, Turkey. October 1-11, 1993
84. M. El Shahawy, M.D., "Hypertrophic Cardiomyopathy: Management with Beta Adrenergic Blockers, Calcium Channel Blockers, DDD Permanent Pacing, or Surgery?" presented at the 40th Anniversary Meeting of the American Medical Society of Vienna. March 26, 1993. Vienna, Austria.
85. M. El Shahawy, M.D. "Hypertrophic Obstructive Cardiomyopathy: Management with Beta Blocker, Calcium Channel Blocker, or Surgery?" presented at the 5th Annual, First International Cardiovascular Symposium, jointly sponsored by the University of Florida and the Cardiovascular Institute of Sarasota. Cairo Egypt. November 20-29, 1992.
86. M. El Shahawy, et. al.; "Magnesium Deficiency and the Hyperthyroid Heart" presented at the First International Symposium on Magnesium Deficiency in the Human Pathology in Vittel, France; May 9-19, 1971.

**Directorships of National Cardiovascular Symposiums:**

1. Program Director of the 23/23/23 Annual National CardioSarasota Congress on Cardiovascular Disease Prevention and Optimal Treatment. Jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota, and The Florida Medical Association. In Cooperation with University of Minnesota, Center for Cardiovascular Disease Prevention, Sarasota Memorial Healthcare System, Association of Black Cardiologists (ABC) and American College of Cardiology, Florida Chapter, February 3-4, 2023 in Sarasota, Florida
2. Program Director of the 22/22/22 Annual National CardioSarasota Congress on Cardiovascular Disease Prevention and Optimal Treatment. Jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota, and The Florida Medical Association. In Cooperation with University of Minnesota, Center for Cardiovascular Disease Prevention, Sarasota Memorial Healthcare System, Association of Black Cardiologists (ABC) and American College of Cardiology, Florida Chapter, February 4-5, 2022 in Sarasota, Florida
3. Program Director of the 21/21/21 Annual National Sarasota Congress on Cardiovascular Disease Prevention and Optimal Treatment: Update 2021. Jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota, and The Florida Medical Association. In Cooperation with University of Minnesota, Center for Cardiovascular Disease Prevention, Sarasota Memorial Healthcare System, Association of Black Cardiologists (ABC) and American College of Cardiology, Florida Chapter,

May 28-30, 2021 in Sarasota, Florida.

1. Faculty 2nd Annual Scientific Advisory Clinical Conference (SACC) Changes in the Clinical Management of Patients with or at High Risk of Cardiovascular Disease Events- Chicago, Illinois, March 27, 2020
2. Program Director of the 20/20/20 Annual National Sarasota Congress on Cardiovascular Disease Prevention: Update 2020. Jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota, and The Florida Medical Association. In Cooperation with University of Minnesota, Center for Cardiovascular Disease Prevention, Sarasota Memorial Healthcare System, Association of Black Cardiologists (ABC) and American College of Cardiology, Florida Chapter, February 7-9, 2020 in Sarasota, Florida.
3. Program Chairperson Current Trends in Cardiovascular and Cardiometabolic Disease Prevention, and Updates in Cardiac Devices and Advanced Cardiac Failure. Jointly provided by Association of Black Cardiologists, Inc, and International Society for Cardiovascular Disease Prevention (ISCVDP) October 12, 2019, in Los Angeles, California
4. Program Director of the 19th Annual National Sarasota Congress on Cardiovascular Disease Prevention: Update 2019. Jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVDP), The Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota and The Florida Medical Association. In Cooperation with University of Minnesota, Center for Cardiovascular Disease Prevention, Sarasota Memorial Healthcare System, Association of Black Cardiologists (ABC) and American College of Cardiology, Florida Chapter, February 1-2, 2019 in Sarasota, Florida.
5. Program Director of the 18th Annual National Sarasota Congress on Cardiovascular Disease Prevention: Update 2018. Jointly provided by The International Society for Cardiovascular Disease Prevention (ISCVP), The Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota and The Florida Medical Association. In Cooperation with University of Minnesota, Center for Cardiovascular Disease Prevention, Sarasota Memorial Healthcare System, Association of Black Cardiologists (ABC) and American College of Cardiology, Florida Chapter, February 2-3, 2018 in Sarasota, Florida.
6. Program Director of the 13th Annual Cardiovascular Symposium Cardiology Update 2017: From Intervention to Prevention Time to Focus on Early Cardiovascular Health Assessment and Disease Prevention. Jointly sponsored by Cardiovascular Health Assessment Center, Cardiovascular Center of Sarasota Foundation for Research and Education. In cooperation with Sarasota Memorial Healthcare Foundation and University of Minnesota and Florida Medical Association (FMA) February 3- 4th, 2017in Sarasota, Florida.
7. Program Director of the 12th Annual Cardiovascular Symposium Cardiology Update 2016: From Intervention to Prevention Time to Focus on Early Cardiovascular Health Assessment and Disease Prevention. Jointly sponsored by Cardiovascular Health Assessment Center, Cardiovascular Center of Sarasota Foundation for Research and Education. In cooperation with Sarasota Memorial Healthcare Foundation and University of Minnesota and Florida Medical Association (FMA) February 5-6, 2016, Sarasota, Florida.
8. Program Director of the 11th Annual Cardiovascular Symposium Cardiology Update 2015: Time to Focus on Early Cardiovascular Disease Prevention. Jointly sponsored by Cardiovascular Health Assessment Center of Sarasota at The Cardiovascular Center of Sarasota, Sarasota Memorial Healthcare Foundation and Sarasota Memorial Healthcare System. In cooperation with The American Society for Preventive Cardiology (ASPC), University of Minnesota Center for Cardiovascular Disease Prevention and Florida Medical Association (FMA), February 7, 2015 in Sarasota, Florida.
9. Program Director of the 10th Annual Early Cardiovascular Disease Risk Assessment Symposium: Update 2014 From Sick Care to Health Care. Jointly sponsored by Cardiovascular Health Assessment Center at The Cardiovascular Center of Sarasota, Doctors Hospital of Sarasota, and Sarasota Memorial Healthcare Foundation. In cooperation with The American Society for Preventive Cardiology (ASPC), University of Minnesota Center for Cardiovascular Disease Prevention and Florida Medical Association (FMA), February 1st, 2014.
10. Program Director of the 10th Annual Early Cardiovascular Disease Risk Assessment Symposium: Update 2014 From Sick Care to Health Care. Jointly sponsored by Cardiovascular Health Assessment Center at The Cardiovascular Center of Sarasota, Doctors Hospital of Sarasota, and Sarasota Memorial Healthcare Foundation. In cooperation with The American Society for Preventive Cardiology (ASPC), University of Minnesota Center for Cardiovascular Disease Prevention and Florida Medical Association (FMA), February 1st, 2014.
11. Program Director of the 8th Annual Cardiovascular Symposium: Cardiology Update 2012 Novel Approach for Cardiovascular Disease Risk Assessment and Prevention in 2012. Jointly sponsored by Sarasota Memorial Healthcare Foundation and Cardiovascular Center of Sarasota, February 4th, 2012 in Sarasota, Florida.
12. Program Chairperson of the 24th Annual Scientific Sessions “From Intervention to Prevention”. Jointly provided by Association of Black Cardiologists, Inc, and International Society for Cardiovascular Disease Prevention (ISCVDP) April 2, 2011 in New Orleans, Louisiana.
13. Program Director of the 7th Annual Cardiovascular Symposium: Cardiology Update; “From Intervention to Prevention” Cardiovascular Disease Prevention in the 21st Century; February 2011. Jointly Sponsored by Sarasota Memorial Healthcare System and Cardiovascular Center of Sarasota.
14. Program Director of the 6th Annual Cardiovascular Symposium: Cardiology Update; Cardiovascular Disease Prevention in the 21st Century; February 2010. Jointly Sponsored by Sarasota Memorial Healthcare System and Cardiovascular Center of Sarasota.
15. Program Director of the 5th Annual Cardiovascular Symposium: Cardiology Update; Cardiovascular Disease Prevention in the 21st Century; February 2009. Jointly Sponsored by Sarasota Memorial Healthcare System and Cardiovascular Center of Sarasota.
16. Program Director of the 4th Annual Cardiovascular Symposium: Cardiology Update 2008. February 2008. Jointly Sponsored by Sarasota Memorial Healthcare System, and Cardiovascular Center of Sarasota.
17. Program Director of the 3rd Annual Cardiovascular Symposium: Cardiology Update 2007, March 2007, jointly sponsored by Sarasota Memorial Healthcare System and Cardiovascular Center of Sarasota.
18. Program Director of the 2nd Annual Cardiovascular Symposium: Cardiology Update 2006, February 2006, Jointly Sponsored by: Sarasota Memorial Healthcare System and Cardiovascular Center of Sarasota.
19. Program Director of the 1st Annual Cardiovascular Symposium: Cardiology Update 2005 held at SMH Auditorium on Saturday, February 11, 2005, Jointly Sponsored by: Sarasota Memorial Healthcare System and Cardiovascular Center of Sarasota.
20. Co-Chairman of one of the Scientific Sessions of the 43rd Annual Meeting of the American College of Cardiology in Atlanta, Georgia; March 14-19, 1984.
21. Program Director of the 4th Annual Cardiovascular Symposium jointly sponsored by the University of Florida and the Cardiovascular Institute of Sarasota, held in Sarasota, FL; December 13-15, 1991.
22. Program Director of the 3rd Annual Cardiovascular Symposium jointly sponsored by the University of Florida and the Cardiovascular Institute of Sarasota, held in Sarasota, FL; December 7-8, 1990.
23. Program Director for the 2nd Annual Cardiovascular Symposium jointly sponsored by the University of Florida and Doctors Hospital of Sarasota, held in Sarasota, FL; December 1-2, 1989.
24. Program Director of the 1st Annual Cardiovascular Symposium jointly sponsored by the University of Florida and Doctors Hospital of Sarasota, held in Sarasota, FL; December 2-3, 1988.
25. Program Director of the First Non-Invasive Cardiovascular Evaluation 1974 Sponsored by the University of Florida College of Medicine in Cooperation with the Division of Continuing Education, January 24th – 25th, 1974, Gainesville, Florida.

**Directorships of International Cardiovascular Symposiums**

1. Program Director of the 31st International Cardiovascular Disease Prevention Congress Organized by The International Society for Cardiovascular Disease Prevention, Cardiovascular Health Assessment Center and the Cardiovascular Center of Sarasota Foundation for Research and Education. In cooperation with the University of Minnesota Center for Cardiovascular Disease Prevention, Sarasota Memorial Healthcare System, Association of Black Cardiologists (ABC), and the American College of Cardiology, Florida Chapter held in Arusha, Tanzania, August 24-25, 2023.
2. Program Director of the 29th International Cardiovascular Disease Prevention Congress Organized by The International Society for Cardiovascular Disease Prevention, Cardiovascular Health Assessment Center and the Cardiovascular Center of Sarasota Foundation for Research and Education. In cooperation with the University of Minnesota Center for Cardiovascular Disease Prevention, Sarasota Memorial Healthcare System, Association of Black Cardiologists (ABC), and the American College of Cardiology, Florida Chapter held in Venice, Italy and Split, Croatia and Athens, Greece on September 25-October 2, 2021.
3. Chairperson for the “Icosalip Launch Event in Egypt, Hypertriglyceridemia; The Forgotten Risk! at CardioLuxor 2020, Luxor, Egypt, January 9, 2020
4. Chairperson for Women and CVD at 21st Annual Meeting of Preventive Cardiology and Rehabilitation Working Group, CardioPrevent 2019, Cairo, Egypt, November 7, 2019
5. Panelist- Session 2 for 21st Annual Meeting of Preventive Cardiology and Rehabilitation Working Group, CardioPrevent 2019 Cairo, Egypt November 6, 2019
6. Program Director of the 28th International Cardiovascular Disease Prevention Congress Organized by The International Society for Cardiovascular Disease Prevention, Cardiovascular Health Assessment Center and the Cardiovascular Center of Sarasota Foundation for Research and Education. In cooperation with the University of Minnesota Center for Cardiovascular Disease Prevention, Sarasota Memorial Healthcare System, Association of Black Cardiologists (ABC), and the American College of Cardiology, Florida Chapter held in Lisbon, Portugal and Malaga, Spain July 13-20, 2019
7. Co-Chair of the X International Conference on Arterial Hypertension and Cardiovascular Disease Prevention, Vitebsk, Belarus May 30-31, 2019
8. Session Co-Chair at CardioRisk 2018 in Hurghada, Egypt November 21-24, 2018
9. Co-Chair of the 20th Annual Meeting of Preventive Cardiology & Rehabilitation Working Group of the Egyptian Society of Cardiology, Cairo, Egypt, November 15-16, 2018
10. Program Director of the 31st Annual, 27th International Cardiovascular Disease Prevention Congress Organized by The International Society for Cardiovascular Disease Prevention, Cardiovascular Health Assessment Center and the Cardiovascular Center of Sarasota Foundation for Research and Education. In cooperation with the University of Minnesota Center for Cardiovascular Disease Prevention, Sarasota Memorial Healthcare System, Association of Black Cardiologists (ABC), and the American College of Cardiology, Florida Chapter held in Paris and Normandy Countrysides, France July 22- 29, 2018.
11. Program Director of the 30th Annual, 26th International Cardiovascular Disease Congress. Sponsored by the Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota Foundation for Research and Education, International Society for Cardiovascular Disease Prevention (formerly CVIS), in cooperation with the University of Minnesota, Center for Cardiovascular Disease Prevention, Association of Black Cardiologists (ABC) and American Society for Preventive Cardiology (ASPC) held in Reyjavik, Iceland to London, England June 1 thru June 10, 2017
12. Session Chairman (115) at the 44th Annual International Congress of the Egyptian Society of Cardiology Cairo, Egypt. February 22, 2017.
13. Session Chairman (47) at the 44th Annual International Congress of the Egyptian Society of Cardiology Cairo, Egypt. February 21, 2017.
14. Session Chairman (37) at the 44th Annual International Congress of the Egyptian Society of Cardiology Cairo, Egypt. February 21, 2017.
15. Program Director of the 29th Annual, 25th International Cardiovascular Symposium. Sponsored by the Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation for Education and Research, and Sarasota Memorial Healthcare Foundation in cooperation with the American Society for Preventive Cardiology held in Italy, Croatia and Slovenia, Jun 7 -16 -2016
16. Program Director of the 28th Annual, 24th International Cardiovascular Symposium. Sponsored by the Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation for Education and Research, and Sarasota Memorial Healthcare Foundation in cooperation with the American Society for Preventive Cardiology held in Ecuador and Peru July 3-21, 2015.
17. Program Director of the 27th Annual, 23rd International Cardiovascular Symposium. Sponsored by the Cardiovascular Health Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation for Education and Research, and Sarasota Memorial Healthcare Foundation in cooperation with the American Society for Preventive Cardiology held in Vienna, Budapest, and Bucharest June 2014.
18. Chair Session on Novel Anticoagulants, World Congress of Cardiology, Melbourne, Australia, May 2014.
19. Program Director of the 26th Annual, 22nd International Cardiovascular Symposium. Sponsored by the Cardiovascular Disease Assessment Center at The Cardiovascular Center of Sarasota, CVIS Foundation For Education And Research, and Sarasota Memorial Healthcare Foundation held in Sweden, Russia, Poland and Germany June 2013.
20. Program Director of the 25th Annual, 21st International Cardiovascular Symposium. Sponsored by the Cardiovascular Disease Assessment Center, The Cardiovascular Center of Sarasota, CVIS Foundation for Education and Research, and Sarasota Memorial Healthcare Foundation held in England and Norway, June 2012.
21. Program Director of the 24nd Annual, 20th International Cardiovascular Symposium. Sponsored by the Cardiovascular Institute of Sarasota Foundation, Sarasota Memorial Health Care System and Foundation, and the Cardiovascular Division of the University of South Florida, held in South Africa, July 2011.
22. Program Director of the 23nd Annual, 18th International Cardiovascular Symposium. Sponsored by the Cardiovascular Institute of Sarasota Foundation, Sarasota Memorial Health Care System and Foundation, and the Cardiovascular Division of the University of South Florida, held in Thailand, Vietnam, Malaysia and Singapore. November 2010.
23. Program Director of the 22nd Annual, 18th International Cardiovascular Symposium. Sponsored by the Cardiovascular Institute of Sarasota Foundation, Sarasota Memorial Health Care System and Foundation, and the Cardiovascular Division of the University of South Florida, held in Switzerland, Germany, France, and Holland. September 2009.
24. Program Director of the 21st Annual, 17th International Cardiovascular Symposium. Sponsored by the Cardiovascular Institute of Sarasota Foundation, Sarasota Memorial Health Care System and Foundation, and the Cardiovascular Division of the University of South Florida, held in Italy, Ukraine, Romania, Turkey and Greece, August 2008.
25. Program Director of the 20th Annual, 16th International Cardiovascular Symposium. Sponsored by the Cardiovascular Institute of Sarasota Foundation, Sarasota Memorial Health Care System and Foundation, and the Cardiovascular Division of the University of South Florida, held in India, October 2007
26. Program Medical Director and Instructor for International Symposium sponsored by the American Heart Association for BLS/ACLS, and Instructor Course in New Delhi, India at Max Health Care Institution, October 2007
27. Program Director of the 19th Annual, 15th International Cardiovascular Symposium. Sponsored by the Cardiovascular Institute of Sarasota Foundation, Sarasota Memorial Health Care System and Foundation, and the Cardiovascular Division of the University of Florida, held in Egypt, Italy, Turkey, and Greece, October 2006.
28. Program Director of the 18th Annual, 14th International Cardiovascular Symposium. Sponsored by the Cardiovascular Institute of Sarasota Foundation, Sarasota Memorial Health Care System and Foundation and the Cardiovascular Division of the University of Florida. Held in The Republic of Seychelles, Madagascar and Mauritius, November 28-December 12, 2005.
29. Program Director of the 17th Annual, 13th International Cardiovascular Symposium. Sponsored by the Cardiovascular Institute of Sarasota Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in Austria, Slovenia, and Italy, July 2004.
30. Program Director of the 16th Annual, 12th International Cardiovascular Symposium sponsored by the Cardiovascular Institute of Sarasota Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in Spain, Portugal; October 24 – November 7, 2003.
31. Co-Chair 4th Annual New Year Symposium of the Association of American Black Cardiologists “ABC”, Western Caribbean, December 28, 2002- January 4, 2003.
32. Program Director of the 14th Annual, 10th International Cardiovascular Symposium sponsored by the Cardiovascular Institute of Sarasota Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in the Caribbean Island; October 16 – 28, 2001.
33. Program Director of the 15th Annual, 11th International Cardiovascular Symposium sponsored by the Cardiovascular Institute of Sarasota Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in England, Scotland and Ireland; August 1 – 15, 2002.
34. Program Director of the 13th Annual, 9th International Cardiovascular Symposium sponsored by the Cardiovascular Institute of Sarasota Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in Australia and New Zealand; October 12 – 28, 2000.
35. Session Chairman at the Annual Meeting of the Egyptian Society of Atherosclerosis, January 22nd – 25th, 2000, Cairo, Egypt.
36. Guest Faculty at the 4th World Congress of Echocardiography and Vascular Ultrasound, January 19th – 21st, 2000, Cairo, Egypt.
37. Program Director of the 12th Annual, 8th International Cardiovascular Symposium sponsored by CVIS Foundation, Doctors Hospital of Sarasota and the Cardiovascular Division of the University of Florida in cooperation with The Argentinean Society of Cardiology held in South America "from Santiago, Chile to Buenos Aires, Argentina" November 19 - December 7, 1999.
38. Program Director of the 11th Annual, 7th International Cardiovascular Symposium sponsored by the Cardiovascular Institute of Sarasota Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in China and the Orient; October 3-19, 1998.
39. Program Director of the 10th Annual, 6th International Cardiovascular Symposium sponsored by the CVIS Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in Paris, France and Cape Town, South Africa; November 21-December 4, 1997.
40. Program Director of the 9th Annual, 5th International Cardiovascular Symposium sponsored by the CVIS Foundation, Doctors Hospital of Sarasota, and the Cardiovascular Division of the University of Florida, held in London, England, Scandinavia, and St. Petersburg, Russia; August 20-September 4, 1996.
41. Program Director of the 8th Annual, 4th International Cardiovascular Symposium jointly sponsored by the University of Florida and the Cardiovascular Institute of Sarasota, held in Rome, Italy and Barcelona, Spain; September 26-October 9, 1995
42. Program Director of the 7th Annual, 3rd International Cardiovascular Symposium jointly sponsored by the University of Florida, University of Vienna, and the Cardiovascular Institute of Sarasota, held in Vienna, Prague, Bratislava, and Budapest; September 15-27, 1994.
43. Program Director of the 6th Annual, 2nd International Cardiovascular Symposium jointly sponsored by the University of Florida and the Cardiovascular Institute of Sarasota, held in Athens, Greece and Istanbul, Turkey; October 1-11, 1993.
44. Program Director of the 5th Annual, 1st International Cardiovascular Symposium jointly sponsored by the University of Florida and the Cardiovascular Institute of Sarasota, held in Cairo, Egypt; November 20-29, 1992.

**CME GRAND ROUNDS AT SARASOTA MEMORIAL HOSPITAL**

**SARASOTA, FLORIDA**

Over 30 one-hour CME lectures at the Grand rounds of Sarasota Memorial Hospital in Sarasota, Florida on various cardiology topics from intervention to prevention, including several lectures on novel approaches for early detection of cardiovascular disease utilizing novel tools and risk scoring system.

**CME SPEAKER PROGRAMS**

National Faculty for CME Program with Expert Exchange

National Faculty for CME with NACE

**PUBLIC LECTURES**

**Over 500** of community service lectures on many cardiovascular topics of public interest which were held at the auditoriums of Sarasota Memorial Hospital, Doctors Hospital of Sarasota. And many other locations in Sarasota County including Civic Clubs

**CIVIC ORGANIZATIONS PAST AND PRESENT**

* Member of the Board of Directors of Florida/Puerto Rico Chapter of the American Heart Association
* Co-Chair for the Manatee/Sarasota AHA Heart Ball 2005
* Member, Board of Directors, Sarasota County Chamber of Commerce
* YMC
* Ringling Museum
* Selby Gardens
* Sun Coast Heart Association
* Sarasota County Public Health Clinic
* Century Club of Sarasota Memorial Hospital
* Sarasota Opera Society
* New College Library Association
* Boys Club of Sarasota
* Kentucky Colonel